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The	 erythrocytic	 stages	 of	 the	 relapsing	 human	 malaria	 parasite,	
Plasmodium	vivax	(P.	vivax),	preferentially	invades	immature	CD71+	reticulocytes.	
This	strict	tropism	for	nascent	reticulocytes	is	the	primary	reason	for	the	absence	
of	 P.	 vivax	 long	 term	 in	 vitro	 culture.	 Plasmodium	 cynomolgi	 (P.	 cynomolgi),	 a	
closely	related	simian	malaria	parasite,	also	preferentially	 invades	human	CD71+	
reticulocytes,	 however	 it	 can	 be	 cultured	 continuously	 using	 mature	 monkey	








with	 cost	 effective	 human	 serum.	 We	 also	 optimised	 the	 enrichment	 and	
cryopreservation	of	cultured	P.	cynomolgi.		
	
Secondly,	 the	 research	 compared	 the	 functional	 invasion	 characteristics	
between	 P.	 vivax	and	 P.	 cynomolgi	Berok	 erythrocytic	 merozoites.	We	 observed	
both	 P.	 vivax	 and	 P.	 cynomolgi	Berok	 to	 preferentially	 invade	 immature	 CD71+	
human	reticulocytes.	Furthermore,	as	P.	vivax	is	duffy-dependent,	we	incorporated	
the	 use	 of	 Fy6	 2c3	 and	 FyB	 antibodies	 to	 block	 the	 extracellular	 domain	 of	 the	
Duffy	 receptor	 (DARC,	 Fy	 or	 CD234)	 and	 observed	 a	 decrease	 in	 percentage	 of	
invasion	in	both	P.	vivax	and	P.	cynomolgi	Berok	respectively.	Our	data	shows	that	




















of	 immature	 reticulocytes.	We	have	observed	 that	 in	 the	majority	of	 the	donors,	
the	 intron	 2	 region	 of	 the	 underlying	 gene,	 Small	 integral	 membrane	 protein	 1	
(SMIM1),	harbours	the	rs143702418C	and	rs1175550A	genotypes.		
	
Following	 the	 functional	 and	 recombinant	protein	 studies,	we	compiled	a	
series	of	 transmission	electron	micrographs	 (TEMs)	 to	 show	merozoite	 invasion	
with	and	without	Cytochalasin	D,	 trophozoite	maturation,	asexual	multiplication,	
and	 cytoadherence	 to	 neighboring	 erythrocytes	 using	 the	 in	 vitro	 P.	 cynomolgi	
Berok	culture.			
	
In	 summary,	 our	 findings	 emphasized	 the	 role	 for	 in	 vitro	 P.	 cynomolgi	
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RTS,S/AS01	 	 Mosquirix	vaccine	
RT-qPCR	 	 Real-time	 reverse	 transcription	 quantitative	 polymerase	
	 	 	 chain	reaction	
s	 	 	 Second	
S.D.	 	 	 Standard	Deviation	
SDM	 	 	 Site	Directed	Mutagenesis	
SEM	 	 	 Standard	Error	of	the	Mean	
SMRU	 	 	 Shoklo	Malaria	Research	Unit	
spp	 	 	 Species		
SSP	 	 	 Sporozoite	Surface	Protein	
TEM	 	 	 Transmission	Electron	Microscopy	
Tf	 	 	 Transferrin	Protein	
TfR1	 	 	 Transferrin	Receptor	1	Recombinant	Protein	
TRAP	 	 	 Thrombospondin-Related	Anonymous	Protein	
UNDP	 	 	 United	Nations	Development	Programme	
UNICEF	 	 United	Nations	Children's	Fund	
v/v	 	 	 Volume	per	volume	
vir	 	 	 Variant	Interspersed	Repeats	gene	
	 XXIII	
VMP001	 	 Vivax	Malaria	Protein	001	
w/v	 	 	 Weight	per	volume	
WEHI	 	 	 Walter	+	Eliza	Hall	Institute	








Section 1.1: Plasmodium vivax - a relapsing parasite 
1.1.1 A burden for public health in Asia and South America 
Malaria	continues	to	affect	millions	of	people	worldwide,	not	only	causing	
sickness	 and	 death	 but	 also	 an	 incalculable	 burden	 to	 productivity	 and	 social	


















to	 difficulties	 in	 diagnosing	 P.	 vivax	 infections	 (which	 have	 lower	 parasitemias	
than	P.	falciparum),	lack	of	a	P.	vivax	orthologue	of	the	P.	falciparum	histidine-rich	
protein	 2	 (PfHRP2)	 which	 provides	 an	 excellent	 marker	 of	 infection	 in	 rapid	





1.1.2 Overview of P. vivax biology 
P.	vivax	utilises	a	human	host	and	an	insect	vector	to	complete	its	life	cycle	
(Figure	 1.1).	 The	 cycle	 begins	 with	 a	 sporozoite	 inoculation	 via	 a	 bite	 from	 an	
infected	Anopheles	mosquito.	The	sporozoites	which	are	released	from	the	salivary	
glands	of	the	mosquito	and	travel	to	the	liver	within	the	blood	capillaries.	Once	in	
the	 liver	 sinusoids,	 they	 traverse	 multiple	 hepatocytes	 to	 find	 a	 suitable	
parenchymal	 cell	 for	 development.	 As	 with	 P.	 vivax	 and	 P.	 ovale;	 the	 invading	
sporozoite	 can	 either	 develop	 into	 a	 mature	 schizont	 (the	 only	 option	 for	 P.	
falciparum),	 or	 form	a	metabolically	 dormant	 stage	known	as	 a	 hypnozoite.	 The	
timing	of	hypnozoite	activation	varies	significantly,	occurring	as	early	as	~10	days	
or	 one	 to	 two	 years.	When	hypnozoites	 are	 activated,	 they	 develop	 into	mature	
schizonts	 within	 9	 to	 11	 days	 (Thus	 in	 many	 tropical	 areas	 such	 as	
Thailand/Myanmar	 the	 first	relapse	are	often	detected	~21	days	after	 the	 initial	
infection).	 Upon	 maturation,	 each	 liver	 schizont	 releases	 thousands	 (to	 tens	 of	
thousands)	 of	merozoites	 into	 the	 bloodstream,	where	 they	 are	 carried	 through	
the	host	to	invade	their	respective	host	cells	-	immature	reticulocytes	for	P.	vivax	






forms	 (gametocytes)	 which	 are	 required	 for	 continuous	 transmission	 into	 the	
arthropod	 intermediate	 host.	 The	 microgametes	 (male)	 and	 macrogametes	
(female)	are	taken	up	by	female	Anopheles	mosquito	during	blood	meal.	In	the	mid	
gut,	 microgametes	 penetrate	 macrogametes,	 form	 zygotes,	 turn	 into	 ookinetes,	
and	develop	 into	oocyst	on	 the	mosquito	gut	wall.	Once	mature,	 oocysts	 release	
immature	sporozoites	into	hemolymph	to	reach	salivary	glands.	There,	immature	





The	 P.	 vivax	 infected	 mosquito	 injects	 sporozoites	 into	 a	 human	 host	 during	 a	
blood	 meal.	 The	 sporozoites	 then	 travel	 to	 the	 liver,	 where	 they	 invade	
hepatocytes	 amd	 develop	 either	 into	 liver	 schizonts	 or	 hypnozoites.	 Liver	
schizonts	mature	and	rupture	releasing	merozoites	into	the	bloodstream	to	invade	
reticulocytes.	The	 freshly	 invaded	merozoites	develop	 through	 ring,	 trophozoite,	
and	 schizont	 stages	 replicating	 asexually	 to	 produce	 about	 16	 to	 24	merozoites	
which	are	then	released	during	egress.	Some	intraerythrocytic	stages	develop	into	
the	sexual	forms	of	the	parasite	-	microgametocytes	(male)	and	macrogametocytes	
(female).	When	 the	mosquito	 takes	 another	 blood	meal,	 the	 sexual	 gametocytes	
are	also	ingested.	Then	the	gametocytes	develop	into	gametes	in	the	insect	gut	and	
fuse	 to	 form	 zygotes.	 The	 zygotes	 develop	 to	 form	 an	 invasive	 ookinete,	 which	
traverse	 the	 midgut	 epithelium	 and	 transform	 into	 an	 oocyst	 on	 the	 gut,	 from	
which	sporozoites	migrate	to	the	salivary	glands	for	injection	into	a	human	host	in	





1.1.3 Current treatment limitations for P. vivax  
Chloroquine	remains	the	first	line	therapy	to	treat	erythrocytic	stages	of	P.	
vivax	in	regions	with	no	known	resistance	(such	as	India),	while	artemisin-based	
combined	 treatments	 (ACTs)	 replace	 chloroquine	 in	 other	 areas	 (most	 of	 South	
East	 Asia)	 [7].	While	 there	 is	 no	 clear	 evidence	 for	 artemisinin	 resistance	 in	 P.	
vivax,	the	very	short	half-life	of	this	drug	(<	4	hours)	precludes	its	ability	to	treat	
blood	stage	infections	arising	from	relapses	[8].	This	is	in	contrast	to	the	extended	
half-life	of	 chloroquine	 (~30	days)	which	at	 least	 covers	early	relapse	 infections	
occurring	at	around	day	20	[9].	Therefore,	ACT	should	include	a	partner	drug	with	
an	extended	half-life	such	as	piperaquine	(median	 time	to	recurrence	~56	days)	
[10].	Although,	 it	 should	be	noted	 that	reduced	susceptibility	 to	piperaquine	has	
been	observed	in	ex	vivo	assays	of	P.	vivax	and	some	clinical	investigations;	thus	it	
remains	 an	 important	 task	 to	 develop	 new	 long	 lasting	 partner	 drugs	 for	 the	
treatment	 of	 P.	 vivax	 blood	 stage	 infections	 [7,	 11].	 Even	 though	 ACTs	 are	
successful	with	blood	parasite	biomass	reduction,	it	nonetheless	developed	partial	
resistant	 parasites	 with	 delayed	 clearance	 in	 Greater	 Mekong	 Subregion	
(Southeast	Asia)	[12].		
	
While	 P.	 vivax	 blood	 stage	 parasites	 are	 relatively	 easier	 to	 target	 than	
those	of	P.	falciparum	(which	 is	now	extensively	 resistant	 to	many	antimalarials	
including	some	ACTs);	hypnozoites	remain	unaffected	by	all	blood	schizonticides	
and	 thus	 remains	 a	 hidden	 reservoir	 in	 the	 liver	 (it	 should	 be	 noted	 that	
atovaquone	 does	 affect	 the	 actively	 growing	 liver	 schizonts)	 [13].	 Currently	 the	
only	 antimalarials	 that	 can	 effectively	 target	 P.	 vivax	 hypnozoites	 are	 the	 8-
aminoquinolines;	primaquine	and	tafenoquine	[14,	15].	However	due	to	the	risk	of	
hemolytic	 anaemia	 associated	 with	 8-aminoquinolines,	 primaquine	 remains	
contraindicated	 for	 treating	 pregnant	 women	 and	 patients	 with	 glucose-6-
phosphate	dehydrogenase	(G6PD)	deficiency	infected	with	P.	vivax	[16].	This	risk	
is	 particularly	 evident	with	 the	 recently	 FDA-approved	 single-dose	 anti-malarial	
8-aminoquinoline,	 Tafenoquine;	 which	 has	 a	 half-life	 of	 ~16	 days	 compared	 to	
primaquine’s		half-life	of	~	14	hours	[15].		
	
Amongst	 the	 increasing	 reports	 of	 multidrug	 resistance	 in	 vivax	 malaria	
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and	 challenges	 associated	 with	 developing	 safe	 and	 effective	 radical	 cure	
(eradication	 of	 hypnozoites),	 the	 silver	 lining	 lies	 within	 the	 vaccine	 against	
relapsing	malaria.	The	discovery	 that	P.	vivax’s	 invasion	of	 erythrocytes	 is	Duffy	





1.1.4 Natural selection limits P. vivax infection (With special 
reference to Duffy blood group dependence) 
Fever	 therapy	 using	 P.	 vivax	 was	 the	 most	 successful	 treatment	 for	
neurosyphillis	 patients	 in	 1919	 [17].	 However,	 the	 effectiveness	 of	 this	 fever	
therapy	was	 limited	 in	African-Americans,	who	were	 found	 to	 be	 resistant	 to	P.	
vivax	 infections	[18].	 	 This	was	because	 sub	 Saharan	African	populations	have	 a	
unique	 genotype	 which	 naturally	 limits	 spread	 of	 P.	 vivax	 disease.	 The	 Duffy	
negative	 (Fya-b-)	 genotype	 do	 express	 Duffy	 antigen	 receptor	 for	 chemokines	
(DARC	or	 Fy)	 on	 endothelial	 cells	 but	 not	 on	 erythrocytes	 (CD234)	 [19].	 This	 is	
due	to	a	point	mutation	(Nucleotide	33:	Tyrosine	to	Cytosine)	located	in	the	GATA	
box	motif	located	within	the	promoter	region	of	FY*B	allele,	which	inhibits	GATA	
transcription	 factor	 binding,	 and	 in	 turn	 silenced	 Fy	 protein	 expression	 on	
myeloid	cells	[20].		
	
The	 Fy	 protein	 is	 structurally	 similar	 to	 G-protein	 coupled	 receptors	
(GPCRs),	 yet	 lacks	 a	 DRY	 motif	 and	 does	 not	 trigger	 GPCR	 signalling	 cascade.	
Instead,	 Fy	 protein	 functions	 in	 angiogenic	 and	 angiostatic	 processes,	 interacts	
with	chemokine	ligands	such	as	CCL2,	5,	7,	8,	and	17,	and	CXC-chemokine	ligands	
1,	 5	 and	 8.	 Structurally,	 the	 myeloid	 Fy	 protein	 is	 a	 seven-transmembrane	
glycoprotein	 with	 an	 exocellular	 NH2-terminus	 and	 contains	 three	 other	





An	 illustration	 of	 the	 7-transmembrane	 Duffy	 antigen.	 The	 amino	 acid	 residues	
predicted	to	comprise	the	P.	vivax	binding	region	are	marked	in	red	(Chitnis	et	al.,	
1996).	 Amino	 acid	 sequence	 polymorphisms	 indicating	 their	 respective	
phenotypes	are	located	on	residues	42	(Glycine	(G)	and	Aspartic	acid	(D)	for	Fya	
and	 Fyb	 respectively),	 89	 (Arginine	 (R)	 and	 Cysteine	 (C)	 for	 Fyb	 and	 Fybweak	
respectively)	 and	 100	 (Adenine	 (A)	 vs.	 Threonine	 (T)).	 Glycosylation	 sites	 are	
identified	 at	 Asparagine	 (N)	 amino	 acid	 residues	 16	 and	 27.	 The	 illustrated	
tertiary	 structure	 within	 the	 cell	 membrane	 is	 depicted	 in	 the	 inset.	 Figure	 1.2	
obtained	 from	 Zimmerman	 PA,	 et	 al.,	 Red	 blood	 cell	 polymorphism	 and	
susceptibility	to	Plasmodium	vivax.	Adv	Parasitol.	2013;81:27-76	with	permission.	
	
Surprisingly,	 a	 link	 between	 FY	 genotype	 and	 P.	 vivax	 infection	was	 also	
reported	 in	 Papua	 New	 Guinea	 [22].	 Although	 the	 observed	 link	 was	 not	
statistically	 significant,	 homozygous	 FY*A/FY*Anull	 	 individuals	 showed	 lower	 P.	
vivax	infection	than	FY*A/FY*A	genotype.	Furthermore,	preliminary	data	suggests	
an	 emergence	 of	 individuals	 with	 reduced	 FyA	 protein	 on	 erythrocytes	 with	
homozygous	 FY*A/FY*Anull	 genotype.	 The	 location	 of	 this	mutation	 is	 similar	 to	
Fya-b-	 individuals,	 with	 Tyrosine	 swapped	 to	 Cytosine	 at	 nucleotide	 46,	 which	
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hinders	GATA-1	binding	to	the	promoter	region	on	FY*A	allele.		
Despite	 limited	P.	vivax	disease	 in	Duffy-null	 individuals,	P.	vivax	infection	
containing	 low	 parasitaemias	 have	 been	 observed	 in	 Duffy-negative	 individuals	
from	 Kenya,	 Amazon,	 Madagascar,	 Congo,	 Uganda	 and	Mauritania	 [23-27].	 This	
indicates	an	alternative	ligand	utilized	by	Duffy-dependent	P.	vivax	to	infect	Duffy-
null	individuals.	However,	there	is	much	debate	due	to	the	fact	that	the	technology	
to	detect	 extremely	 low	P.	vivax	parasitaemia	only	 surfaced	 in	 recent	 years,	 and	
that	there	has	always	been	a	small	undetected	pool	of	P.	vivax-infected	Duffy-null	
individuals.	Nonetheless,	 it	was	proposed	 that	Duffy-null	 individuals	with	 ‘leaky’	













Section 1.2: P. vivax vaccine strategies 
1.2.1 Rationale for P. vivax vaccine development 
Small	 pox	 disease	 eradication	 credited	 to	 Edward	 Jenner,	 was	 primarily	
based	 on	 the	 old	 tradition	 of	 training	 immune	 systems	 to	 combat	 disease.	 The	
approach	was	similarly	applied	to	malaria	parasites	where	a	P.	falciparum	malaria	
vaccine,	 RTS,S/AS01	 (commercial	 name	 Mosquirix),	 could	 provide	 individuals	
who	 have	 not	 acquired	 malaria	 immunity	 an	 opportunity	 to	 be	 exposed	 to	 P.	




While	 the	 Mosquirix	 vaccine	 is	 being	 optimized	 to	 confer	 stronger	
protection	 to	 P.	 falciparum,	 researchers	 examined	 the	 protective	 immunity	
developed	in	individuals	exposed	to	long	term	P.	vivax	infections.	It	was	observed	
that	 antibodies	 on	 memory	 B	 cells	 target	 a	 vast	 panel	 of	 antigens	 in	 both	 pre-
erythrocytic	and	erythrocytic	stages	(Figure	1.3)	[29,	30].	Based	on	these	studies,	
it	is	now	advised	to	stimulate	antibodies	towards	multiple	essential	antigens	from	







(A)	 Annotation	 was	 determined	 by	 PlasmoDB	 release	 25.	 Merozoite	 surface	
proteins	 or	 paralogs	 (MSPs),	 early	 transcribed	membrane	 proteins	 (ETRAMPs),	
reticulocyte	binding	proteins	or	precursors	(RBPs),	liver-specific	proteins	(LISPs),	
variable	 surface	 proteins	 (VIRs).	 (B)	 Expression	 stage	 was	 also	 determined	 by	






1.2.2 Current vaccine candidates for P. vivax 
An	 ideal	worldwide	malaria	vaccine	would	be	 required	 to	 simultaneously	
target	pre-erythrocytic,	asexual	and	sexual	erythrocytic	stages	of	P.	falciparum	and	
P.	 vivax.	 A	 study	 which	 subjected	 volunteers	 to	 infective	 bites	 of	 irradiated	 P.	




recruitment	 of	 host	 protein	 -	 exported	 protein	 1	 (Exp	 1),	 etc.	 Of	 these,	 CSP	 is	




In	 P.	 vivax,	CSP	 immunisation	 studies	 are	 also	 examined	 in	 both	 human	
volunteers	 and	 animal	 models.	 The	 P.	 vivax	 circumsporozoite	 (CSV)	 protein	
expressed	in	Saccharomyces	cerevisiae	(CSV-S,S),	contains	repeat	sequences	of	two	
major	 P.	 vivax	 circumsporozoite	 (PvCSP)	 alleles	 VK210	 and	 VK247,	 induced	
PvCSP-specific	antibodies	in	rhesus	macaques	[34].	In	sporozoite	challenge	study,	
66.7%	 of	Aotus	nancymaae	monkeys	 vaccinated	with	Vivax	 Malaria	 Protein	 001	
(VMP001)	showed	sterile	protection	[35],	whereas	in	human	volunteers,	delayed	
parasitaemia	 was	 observed	 [36].	 In	 mice	 innoculated	 with	 P.	 vivax	
thromospondin-related	adhesive	protein	(PvTRAP),	high	antibody	titers	and	CD8+	
T	 cell	 response	 indicated	 strong	 response	 towards	malaria	 antigen	 but	 remains	
unambiguous	to	infection	challenge	[37].	Hence,	although	these	studies	do	elicit	a	




Currently,	 the	 list	 of	P.	 vivax	erythrocytic	 vaccine	 candidates	 investigates	
both	asexual	and	sexual	erythrocytic	antigens.	For	asexual	antigens,	 it	 is	 thought	
that	 Duffy-dependent	 interaction	 in	 P.	 vivax	 could	 be	 targeted	 using	 inhibitory	
antibodies	 against	 PvDBP.	 The	 monoclonal	 antibodies	 retrieved	 from	
asymptomatic	 patients	 have	 shown	 to	 be	 strain-transcendent,	 confer	 protective	
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immunity,	 and	 reduce	 P.	 vivax	 invasion	 to	 reticulocytes	 in	 vitro	 [38-41].	 In	
addition,	 naturally-acquired	 antibodies	 to	 other	 antigens	 are	 also	 being	
investigated	 such	 as	 reticulocyte	 binding	 proteins	 (RBPs)	 [42,	 43],	 merozoite	
surface	 proteins	 (MSPs)	 [44-46],	 apical	 membrane	 antigen	 (AMA)	 [47-49],	 and	
sexual	/	ookinete	antigens	P25	and	P28	proteins	(Pvs25	and	Pvs28	respectively)	
[36,	 50-52].	 Thus,	 it	 is	 hoped	 that	 by	 stimulating	 an	 immunity	 which	 closely	




1.2.3 Challenges in studying P. vivax 
A	 significant	 reason	 behind	 the	 many	 advances	 in	 understanding	 P.	
falciparum,	were	made	by	studying	in	vitro	models.	However,	the	parasitic	ligand-
receptor	 interactions	 essential	 in	 P.	 falciparum	 are	 not	 translatable	 to	 P.	 vivax.	
Furthermore,	unlike	P.	falciparum,	it	is	still	not	possible	to	continuously	culture	P.	










4.	 Ability	 to	 screen	 novel	 therapeutics	 and	 vaccines	 in	 a	 repeatable	 and	
consistent	manner	
	
Numerous	 attempts	 have	 been	 made	 to	 culture	 P.	 vivax	 to	 provide	 a	
platform	 for	 answering	 questions	 with	 the	 exception	 of	 Golenda	 et	 al,	 who	
adequately	 cultured	 P.	 vivax	 for	 a	 period	 of	 2	 weeks	 [60].	 All	 other	 methods	
reported	 recently	 have	 not	 been	 repeated.	 Hence	 use	 of	 an	 in	 vitro	 continuous	






Section 1.3: P. cynomolgi – an in vitro model for erythrocytic P. vivax  
1.3.1 P. cynomolgi – a relapsing southern Asian macaque malaria 
P.	cynomolgi;	biologically	and	morphologically	similar	to	P.	vivax,	was	first	
identified	 in	 imported	M.	 fascicularis	 from	 Java	 by	 Martin	 Mayer	 in	 1907	 [62].	
Similar	 to	 P.	 vivax	 in	 many	 ways,	 P.	 cynomolgi	 is	 a	 relapsing	 simian	 malaria	
targeting	 old	 world	 macaques	 and	 occasionally	 zoonotic	 parasites	 in	 humans.	
Whereas	 P.	 falciparum,	 a	 lethal	 form	 of	 human	 malaria,	 shares	 biological	




sections	 [63],	 and	 then	 later	 in	P.	 vivax.	 In	 the	 erythrocytic	 stages,	P.	 cynomolgi	
trophozoites,	 when	 stained	 with	 Wright’s	 giemsa	 stain	 are	 amoeboid,	 and	
demonstrate	the	classic	Shüffner’s	stippling	appearance	that	is	usually	associated	
with	P.	 vivax.	 The	 asexual	 blood	merozoite	multiplies	 every	 48	 h	 and	 are	 often	
observed	at	low	parasitaemias.	Under	Wright’s	stain,	the	sexual	microgametocytes	
of	P.	vivax	and	P.	cynomolgi	 are	 stained	 reddish-purple	 and	macrogametocytes	 a	
light	blue	colour.	
	
Besides	 the	 recently	 re-established	 P.	 cynomolgi	 Berok	 in	 vitro	 culture,	
other	 P.	 cynomolgi	 laboratory	 strains	 include	 Gombak,	 Cambodian,	 Rossan,	





1.3.2 In vitro P. cynomolgi erythrocyte culture 
P.	 vivax	 lacks	 an	 in	 vitro	 culture	 platform,	 and	 propagates	 only	 in	 New	
World	 monkeys	 which	 are	 a	 rare	 species	 (not	 the	 ideal	 model	 system)	 [53].	
Although	 P.	 knowlesi,	 an	 Asian	 Old	 World	 monkey	 parasite	 is	 zoonotic,	 it	 is	
distantly	 related	 to	 P.	 vivax	 and	 is	 phenotypically	 dissimilar.	 In	 contrast,	 P.	
cynomolgi,	a	simian	malaria	parasite	that	can	infect	humans,	is	the	sister	taxon	to	
P.	vivax	and	shares	many	genomic	and	biological	traits	(Figure	1.4A)	[61].	Notably,	
P.	 cynomolgi	 infection	 shows	 periodic	 relapses	 caused	 by	 dormant	 hypnozoites	





P.	 cynomolgi	 strain	 adapted	 to	 long	 term	 in	 vitro	 culture	 using	 Rhesus	 monkey	
erythrocytes.	It	was	described	by	the	research	group	that	success	was	most	likely	
due	 to	 completion	 of	 schizogony	 as	 developing	 parasitized	 erythrocytes	 appear	
minimally	enlarged	without	cell	rupture	[64,	66].	However	no	further	publications	
indicated	 use	 of	 P.	 cynomolgi	 Berok	 since,	 until	 a	 recent	 effort	 to	 investigate	
biology	of	P.	vivax	using	P.	cynomolgi	[67].		
	
With	 the	 benefit	 of	 recent	 technology	 advancement,	 new	 insights	 on	 P.	
vivax	biology	are	gained	by	applying	P.	cynomolgi	 in	rheological	studies,	and	high	
throughput	screen	of	anti-malarials	MMV’s	Pathogen	Box.	Furthermore,	the	ability	
to	 culture	 P.	 cynomolgi	Berok	 continuously	 in	 vitro,	 expands	 functional	 studies	
using	genetic	manipulation	to	be	undertaken,	investigation	of	P.	vivax	reticulocyte	








Figure	 1.4	 Phylogenetic	 tree	 and	 the	 orthologous	 relationships	 of	 binding	
ligand	genes	in	P.	vivax	and	its	related	simian	malaria	species.	
(A)	A	maximum	 likelihood	phylogenetic	 tree	generated	using	192	protein	genes	
from	 seven	Plasmodium	species	 (P.	 cynomolgi,	P.	 vivax,	P.	 knowlesi,	P.	 berghei,	P.	
yoelii,	P.	chabaudii,	and	falciparum).	(B)	Copy	number	variations	and	orthologous	
relationships	in	the	duffy	binding	ligand	(dbl)	and	reticulocyte	binding	ligand	(rbl)	





Section 1.4: Molecular basis of erythrocytic Plasmodium merozoite 
proteins 
1.4.1 Process of merozoite invasion 






To	describe	 in	detail,	 a	 free	merozoite	 (about	1	 to	2	μm	 in	size)	 interacts	
with	host	erythrocytes	 in	a	 random/haphazard	 fashion.	Within	a	 few	seconds	of	
recognition,	 the	merozoite	 attaches,	 reorients	 its	 apical	 prominence	 to	 host	 cell	
surface,	 and	 causes	widespread	 deformation	 to	 the	 host	 cell.	 The	 initial	 contact	
remains	 reversible	 until	 junction	 formation	 is	 achieved.	 To	 initiate	 junction	
formation,	 the	merozoite	 releases	micronemal	 and	 rhoptry	 proteins	 encoded	by	
erythrocyte	 binding	 ligand	 (ebl)	and	 rbl	gene	 families	 to	 bind	 essential	 host	 cell	
receptors.	A	parasitophorous	vacuole	membrane	(PVM)	forms	at	the	junction,	and	




One	 of	 the	 first	 malaria	 erythrocytic	 invasion	 ligands	 identified,	 P.	
falciparum	 175-kD	 erythrocyte	 binding	 antigen	 (PfEBA-175)	 is	 a	 homologue	 of	
PvDBP,	 which	 binds	 sialic	 acids	 on	 glycophorin	 A	 (GYPA).	 Unlike	 P.	 vivax,	 P.	
falciparum	 can	 engage	 alternative	 ligand-receptor	 interaction	 to	 invade	 GYPA	
deficient	erythrocytes.	Briefly,	the	erythrocytic	 ligands	are	grouped	to	two	major	
families	of	proteins,	duffy	binding	ligands	(DBL),	and	reticulocyte	binding	ligands	
(RBL)	proteins.	These	 conserved	proteins	 are	 localized	 to	 the	 tight	 junction	and	
undergo	adaptation	to	 invade	specific	host	cells.	 In	cross	species	 interaction,	 the	
role	 of	 DBL	 and	 RBL	 in	 P.	 cynomolgi	 to	 invade	 either	 monkey	 or	 human	
erythrocytes	is	unclear	and	depends	on	multiple	ligand-receptor	interactions	in	a	
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Subcellular	 structure	 of	 a	 P.	 falciparum	 merozoite	 showing	 microneme	 and	
rhoptry	 organelles	 at	 apical	 end.	 (B)	 Merozoite	 invasion	 of	 erythrocytes.	 This	
consists	 of	 initial	 attachment	 and	 reorientation,	 perhaps	 involving	MSPs.	A	 tight	
junction	 attachment	 involves	 high-affinity	 receptor-ligand	 interactions	 between	
the	host	cell	surface	proteins	and	merozoite.	The	tight	junction	is	moved	from	the	
apical	 to	 posterior	 end	 of	 the	 merozoite.	 The	 merozoite	 then	 resides	 in	 a	
parasitophorous	vacuole	after	 invasion.	Figure	1.5	obtained	from	Cowman	AF,	et	





1.4.2 Conserved Duffy preference across species 
In	 P.	 vivax	 and	 P.	 knowlesi,	 merozoite	 invasion	 is	 dependent	 on	 the	
interaction	 between	 DBP	 ligand	 and	 DARC	 receptor.	 To	 determine	 inhibition	
efficiency	 in	P.	vivax,	a	 camelid	monoclonal	 antibody	which	 binds	 22FEDVW26	on	
DARC	removes	P.	vivax	invasion	[21,	69].	Complete	inhibition	was	also	observed	in	
P.	knowlesi	[70],	but	not	in	P.	cynomolgi	Bastianellii	[65].	In	P.	knowlesi,	merozoites	




Figure	 1.6	 Electron	 micrograph	 of	 cytochalasin	 B-treated	 P.	 knowlesi	
merozoite	connected	to	Duffy-negative	human	erythrocyte.		
The	 cytochalasin	 B-treated	P.	knowlesi	merozoite	 is	 connected	 to	Duffy-negative	
















suggests	 retained	 biological	 function.	However,	 duplications	 and/or	 deletions	 of	





descent.	Whereas,	P.	cynomolgi	DBP	2	 (PcyDBP2)	 on	 chromosome	3,	P.	knowlesi	







in	 the	 same	 gene,	 there	 is	 a	 greater	 chance	 for	 diverged	 biological	 functions.	
Hence,	gene	duplication	located	close	to	leaf	nodes	does	not	necessarily	result	 in	
function	divergence.	Figure	1.7	obtained	from	Fang	G,	et	al.,	Getting	started	in	gene	
orthology	 and	 functional	 analysis.	 PLoS	 Comput	 Biol.	 2010;6(3):e1000703	 with	
permission.	
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PvDBP	 region	 II	 (PvDBP-RII),	PvDBP	 region	VI	 from	amino	 acid	 residues	 898	 to	
917	also	showed		high	binding	activity	[75].		
	







1.4.5 Solved structures of DBP-RII interaction 
Key	residues	for	interaction	and	dimer	formation	of	P.	vivax	duffy	binding	
protein	 region	 II	 (PvDBP-RII)	 to	DARC	 complex	 used	 selenate	 to	mimic	 binding.	
The	 structural	 conformation	 showed	 three	 subdomains	 and	 upon	 dimerisation	
produce	a	sulfotyrosine	binding	pocket,	and	a	flexible	asymmetric	flap	for	binding	










and	 drives	 recognition	 of	 DARC.	 Nat	 Struct	 Mol	 Biol.	 2011;18(8):908-14	 with	
permission.	
	
In	 P.	 knowlesi,	 PkDBPα	 binding	 was	 mimicked	 using	 potassium	 gold	
cyanide	[78].	Similar	to	PvDBP-RII,	three	distinct	subdomains	were	identified	with	
subdomain	 1	 located	 in	 the	 middle	 of	 subdomains	 2	 and	 3.	 Site-directed	
mutagenesis	 studies	 which	 reduced	 DARC	 binding	 are	mapped	 to	 subdomain	 2	
[79].		
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1.4.6 PvDBP inhibitory antibodies  
Identification	 of	 broadly	 conserved	 human	 neutralizing	 antibodies	
mediated	by	strain	transcendent	memory	B-cells	recognise	PvDBP-RII	subdomain	
2	 [80].	 Prior	 to	 the	 discovery	 of	 human	 neutralizing	 antibodies,	 murine	
monoclonal	 antibodies	 targeting	PvDBP-RII	 recognise	 subdomain	 1	 (3D10),	 and	
subdomain	3	(tail	end:	2H2,	2D10,	and	helical	surface:	2C6)	(Figure	1.8)	[81].			
	







and	 2H2	 (orange,	 inhibitory	 murine	 monoclonal	 antibody	 2C6	 (green),	 and	
neutralizing	human	monoclonal	antibodies	053054	and	092096	(red).	Figure	1.9	
obtained	from	Urusova	D,	et	al.,	Structural	basis	for	neutralization	of	Plasmodium	
vivax	 by	 naturally	 acquired	 human	 antibodies	 that	 target	 DBP.	 Nat	 Microbiol.	
2019;4(9):1486-96	with	permission.	
	
While	 P.	 vivax	 and	 related	 malaria	 species	 are	 dependent	 on	 DBP-DARC	
interaction,	 a	 humanized	 P.	 knowlesi	 culture	 with	 knockout	 of	 P.	 knowlesi	
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normocyte	 binding	 protein	 Xa	 (PkNBPXa)	 protein	 (a	 homologue	 of	 P.	 vivax	
pseudogene	 reticulocyte	 binding	 protein	 3)	 completely	 abolished	 capacity	 to	 in	
vitro	 culture	using	human	erythrocytes.	This	suggests	 the	rbl	gene	 family	 to	also	
play	an	essential	role	towards	merozoite	invasion	and	survival.	  
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reticulocyte	 receptors	 to	 invade	 reticulocytes	 [82,	 83].	 In	 invasion	 assays	which	
subjected	P.	vivax	to	varying	levels	of	transferrin	receptor	CD71,	reticulocytes	with	
high	 levels	 of	 transferrin	 receptor	 (CD71hi)	 showed	 higher	 proportion	 of	
parasitized	 cells	 than	 CD71lo	 reticulocytes	 [84-86].	 Interestingly,	 the	 transferrin	





1.4.8 Solved structure of PvRBP2B to Transferrin receptor 
Amongst	P.	vivax	RBP	ligands,	PvRBP2b	has	been	solved	to	form	a	complex	
with	 human	 transferrin	 receptor	 1	 (TfR1).	 TfR1,	 also	 referred	 to	 as	 CD71,	 is	 an	
essential	 protein	 responsible	 for	 transporting	 iron	 and	 is	 highly	 expressed	 on	
immature	 reticulocytes	 [86].	 In	 this	 thesis,	 the	 term	TfR1	 refers	 to	 recombinant	
protein,	 and	 CD71	 to	 cell	 differentiation	 marker	 commonly	 associated	 with	
myeloid	cells.	
	
The	 type	 II	 transmembrane	 TfR1	 glycoprotein	 is	 dimeric,	 and	 its	
ectodomain	 consists	 of	 three	 subdomains	 –	 protease-like,	 apical	 and	 helical	
domains	[42].	Fluorescence	resonance	energy	transfer	(FRET)	analysis	and	cryo-
electron	 microscopy	 (Cryo-EM)	 showed	 NH2-terminus	 PvRBP2b	 to	 share	
overlapping	 residues	 in	 apical	 domain	 TfR1	 (Figure	 1.9)	 [42,	 87].	 The	 apical	
domain	of	TfR1	(residues	208	 to	212)	 is	also	utilized	by	Machupo	virus	 (MACV)	
for	cell	entry	[87].	
	
Various	 lengths	 of	 PvRBP2b	 protein	 help	 characterize	 essential	 residues	
required	 for	 reticulocyte	 binding	 [42],	 and	 crystal	 formation	 [88].	 Although	 the	
short	 fragment	 showed	 success	 in	 crystallization	 with	 TfR1,	 the	 longer	 protein	
fragments,	PvRBP2b169-969	 and	PvRBP2b169-1454,	 displayed	 reticulocyte	 binding	 in	
addition	to	complex	formation	with	TfR1	and	Transferrin	(Tf)	via	surface	plasmon	
resonance.	 By	 examining	 the	 binding	 patterns	 between	 the	 protein	 fragments,		







Figure	 1.10	 Surface	 representation	 of	 the	 contact	 amino	 acids	 on	 human	
CD71	for	Machupovirus	and	P.	vivax	binding.	
Surface	 representation	 of	 the	 human	 CD71	 apical	 domain	 (dark	 gray).	 Ligand	
specific	and	overlapping	residues	contacted	by	the	human	heavy	chain	ferritin	(H-
Ft),	 glycoprotein	1	 (GP1)	of	Machupo	virus	and PvRBP2b	of P.	vivax	 are	mapped	
out	 following	 color	 code	 as	 indicated	 in	 legend.	 Figure	 1.10	 obtained	 from	







1.4.9 Antibodies to PvRBP2B and TfR1 












Figure	 1.11	 Surface	 representation	 highlight	 the	 structural	 modes	 of	
inhibition	for	anti-PvRBP2b	antibodies.	
On	 the	 left,	 the	 PvRBP2b	 molecule	 (purple)	 is	 presented	 with	 TfR1	 (green),	 Tf	
(cyan)	and	the	inhibitory-antibody	interaction	sites	as	indicated.	The	middle	and	
right	 cryo-EM	 PvRBP2b-TfR1-Tf	 binding	 complex	 is	 represented	 as	 a	
superposition	of	the	structures	with	3E9,	4F7,	6H1	and	10B12	antibody	fragments.		
Figure	 1.11	 obtained	 from	Gruszczyk	 J,	 et	 al.,	 Cryo-EM	 structure	 of	 an	 essential	
Plasmodium	 vivax	 invasion	 complex.	 Nature.	 2018;559(7712):135-9	 with	
permission.	
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1.4.10 Homologues of PvRBP in related simian malaria parasites	
The	rbl	gene	family	encodes	3	subgroups	of	RBPs	ranging	from	230	to	350	
kDa,	 localized	 to	 the	 apical	 secretory	 organelles	 of	 the	merozoite.	 All	 three	RBP	
groups	 have	 putatively	 functional	 representatives	 in	 the	 P.	 cynomolgi	 genome,	
unlike	 P.	 vivax	 and	 zoonotic	 P.	 knowlesi	 which	 encode	 pseudo	 RBP3	 and	 RBP1	
genes	respectively	[61].	The	presence	of	various	homologues	to	rbl	gene	family	in	
P.	 vivax	 and	 related	 simian	 malaria	 indicates	 diversification	 to	 happen	 before	
speciation	.		
	
In	 P.	 knowlesi,	 rbl	 genes	 are	 encoded	 by	 normocyte	 binding	 ligand	 (nbl)	
gene	family,	with	pseudogene	P.	knowlesi	normocyte	binding	protein	1	(ψPkNBP1)	
to	 PvRBP1	 family	 of	 proteins,	 P.	 knowlesi	 normocyte	 binding	 protein	 Xb	
(PkNBPXb)	 to	 PvRBP2	 proteins,	 and	 P.	 knowlesi	 normocyte	 binding	 protein	 Xa	
(PkNBPXa)	 to	 PvRBP3	 proteins	 [61,	 89].	 PkNBPXa	 is	 essential	 for	 invasion	 to	




PvRBP1b,	 and	 the	PvRBP2	 genes	 to	PvRBP2a,	PvRBP2b,	PvRBP2c,	 and	PvRBP2d	
paralogous	proteins.	 In	both	P.	vivax	 and	P.	cynomolgi,	 gene	pairs	RBP1a/RBP1b	
and	RBP2c/RBP2d	are	adjacent	to	each	other	on	chromosome	7	and	chromosome	




Within	 the	 P.	 cynomolgi	 species,	 phylogenetic	 sequence	 alignment	 of	
RBP1a,	 RBP3,	 and	 DBP1,	 separates	 Berok	 and	 Gombak	 to	 other	 strains	 [93].		
However,	 some	 homologues	 are	missing	 in	 these	 species,	 for	 example	PvRBP1b	




Section 1.5: Study outline  
In	 this	 study,	 the	 main	 objectives	 were	 to	 investigate	 relatedness	 of	
invasion	 biology	 between	 in	 vitro	 cultured	 P.	 cynomolgi	 Berok	 and	 P.	 vivax.	
Chapter	III	demonstrates	the	establishment	of	P.	cynomolgi	Berok	 in	vitro	culture	
at	University	of	Otago.	This	 is	 followed	by	 the	exploration	of	P.	cynomolgi	Berok	
and	 P.	 vivax	 merozoite	 preference	 to	 CD71+	 and	 CD71-	 reticulocytes,	 and	
examination	 of	 antibodies	 targeting	 parasitic	 ligands	 PvDBP	 and	 PvRBP2b,	 and	
host	 receptor	DARC	using	 the	24h	 invasion	 inhibition	assay.	 In	addition,	 growth	
inhibition	 assays	 examined	 antibody	 inhibition	 concentration	 at	 96	 h.	 Through	
internal	and	external	collaborations,	recombinant	homologous	proteins	were	also	
generated	to	determine	if	known	interaction	of	PvDBP	and	PvRBP2b	to	DARC	and	






Chapter	 V	 explores	 SMIM1	 genotype	 in	 cord	 blood	 isolates,	 and	 Rhesus	
factor	in	erythrocytes	of	H.	sapiens	and	M.	fascicularis.	Chapter	VI	shows	ultrafine	
structures	 of	 asexual	 P.	 cynomolgi	 Berok	 merozoite	 development	 and	 rosette	
formation	 in	 infected	 M.	 fascicularis	 erythrocytes	 analysed	 using	 transmission	










The	 time	 line	 (Table	 2.1)	 shows	 the	 development	 in	 investigation	 to	
phenotypic	 invasion	 profile	 of	 P.	 cynomolgi	 using	 established	 in	 vitro	 antibody	
inhibition	 assays	 (Chapter	 2.1),	 and	 ligand-receptor	 combinations	 using	
homologous	 recombinant	 proteins	 (Chapter	 2.2	 –	 Characterisation	 of	 Duffy	
preference,	and	Chapter	2.3	–	Characterisation	of	reticulocyte	preference).		
	
Blood	 group	 antigen	 is	 a	 primary	 factor	 in	 the	 parasitic-host	 recognition	
process.	 In	 this	 thesis,	 the	 genotype	 underlying	 a	 newly	 discovered	 reticulocyte	
blood	 group	 Vel	 antigen,	 Small	 integral	 membrane	 protein	 1	 (SMIM1),	 was	
sequenced	 in	 cord	 blood	 donors	 from	 Mae	 Sod,	 Thailand	 (Chapter	 2.4).	
Furthermore,	in	an	effort	to	adapt	the	in	vitro	P.	cynomolgi	culture	to	propagate	in	
human	 erythrocytes,	 the	 Rhesus	 factor	 (RhD)	 distinctly	 profiled	 human	 and	
simian	erythrocytes	in	a	mix	blood	culture	via	flow	cytometry.		
	
In	 conclusion,	 the	 in	vitro	P.	cynomolgi	Berok	 asexual	 life	 cycle	was	 shown	
using	 transmission	 electron	 micrographs	 (TEMs)	 and	 tomography.	 The	 process	



















































2.1.1 Ethical committees and animal welfare 
M.	 fascicularis	 (cynomolgus	 monkeys)	 were	 maintained	 at	 Monash Animal 
Research Platform (MARP), Gippsland, Australia.	 All	 animals	 were	 housed	 in	
accordance	with	the	Australian	Code	of	Practice	and	the	Laboratory	Animals	Code	
of	 Practice.	 Collection	 of	 blood	 from	 cynomolgus	 monkeys	 followed	 standard	
operating	procedures	within	MARP.	All	import,	export	and	re-export	permits	were	
approved	 by	 Convention	 on	 International	 Trade	 in	 Endangered	 Species	 of	Wild	
Fauna	 and	 Flora	 (CITES).	 Import	 and	 re-export	 declarations	 were	 approved	 by	
Ministry	of	Primary	 Industries	 (MPI),	New	Zealand.	Written	 informed	consents	 to	
use	 donor’s	 peripheral	 blood	 for	 erythrocytes	 and	 serum	 were	 approved	 by	
participants	at	University	of	Otago	
	
2.1.2 P. cynomolgi Berok media components 
Base	 media	 was	 prepared	 with	 RPMI	 1640	 medium	 (Roswell	 Park	 Memorial	
Institute)	supplemented	with	GlutaMAX	(Cat	no.	61870-036,	Gibco)	containing	30	
mM	HEPES	(Cat	no.	H4034,	Sigma-Aldrich),	0.2%	(w/v)	D-glucose	(Cat	no.	G7021,	
Sigma-Aldrich)	 and	 200	 µM	 hypoxanthine	 (Cat	 no.	 4010BC,	 Calbiochem).	
Complete	 growth	 media	 constitutes	 base	 media	 supplemented	 with	 20%	 (v/v)	
heat	inactivated	M. fascicularis serum	or	human	serum	(B+	blood	group).		
	
2.1.3 Macaque naïve blood and serum extraction and preparation  







°C.	 For	 serum	 separation,	 clot	 activator	 tubes	 were	 centrifuged	 at	 2,500	 rpm	









2.1.4 Cryopreservation of P. cynomolgi Berok K2, K4, and K4-A7  
P. cynomolgi parasite	culture	of	predominantly	rings	and	early	trophozoite	stages	
were	 pelleted	 by	 centrifugation	 at	 1,800	 rpm	 (627	 rcf	 xg)	 for	 5	 min	 at	 RT.	




interval	 with	 gentle	 and	 continuous	 swirling	 of	 the	 tube	 to	 prevent	 settling	 of	




2.1.5 Thawing of frozen parasites and routine culture in M. 
fascicularis RBCs  
P. cynomolgi Berok	 K2,	 K4	 or	 K4-A7	 parasite	 cultures	 were	 thawed	 from	 1	mL	
stabilate	cryopreserved	samples	 in	a	37	 oC	waterbath	using	 the	sodium	chloride	




at	 1,800	 rpm	 (627	 rcf	 xg)	 for	 5	 min	 at	 RT,	 supernatant	 discarded	 and	 gently	
swirled	to	agitate	settled	RBCs	before	addition	of	10	mL	base	medium	in	a	drop-
wise	 manner	 combined	 with	 gentle	 tube	 swirls.	 Finally,	 RBCs	 were	 pelleted	 by	
centrifugation	 at	 1,800	 rpm	 (627	 rcf	 xg)	 for	 5	 min	 at	 RT	 and	 adjusted	 to	 5%	
haematocrit	 with	 pre-warmed	 complete	 growth	 media.	 The	 parasitized	
erythrocytes	were	placed	in	a	well	of	a	6	well	plate	(Costar,	Corning)	at	37	°C	in	a	















dried	before	 immersion	 in	10%	Giemsa/phosphate-buffered	 saline	 (PBS)	pH	7.2	
for	 20	 min	 at	 RT.	 Slides	 were	 rinsed,	 dried	 and	 parasitemia	 determined	 by	
counting	 a	 total	 of	 1000	RBCs	under	 light	microscope	 (NIKON	YS100)	 at	 1000X	
magnification	via	 the	100X	oil	 immersion	 lens.	The	number	of	parasites	at	rings,	
trophozoites	 or	 schizonts	 were	 determined	 using	 a	 cell	 counter.	 Total	 %	
parasitemia	was	 determined	 using	 the	 formula:	 Parasitized	RBCs/	Total	 RBCs	 X	
100%.		
	
2.1.7 Enrichment of P. cynomolgi Berok late stages using trypsin and 
percoll 
The enrichment method was adapted from	 an	 invasion	assay	method	specific	 for	P.	
vivax	[69].	The	parasite	culture	was	matured	to	majority	late-stage	parasites,	and	
pelleted	red	blood	cells	(pRBC)	obtained	by	centrifugation	1,800	rpm	(627	rcf	xg)	
for	 5	min	 at	 RT.	 To	minimise	 rosette	 formation,	 the	 pellet	 was	 resuspended	 to	
50%	 hematocrit	 with	 base	 media	 and	 trypsinized	 with	 3	 mL	 of	 0.125%	 w/v	
trypsin-versene/PBS	 (Lonza,	 Thermo	 Fisher	 Scientific)	 for	 15	 min	 at	 37	 °C.	











2.1.8 Enrichment of P. cynomolgi Berok late stages using MACS LD 
columns 
Enrichment	 of	 late	 stage	 parasite	 were	 also	 performed	 with	 freshly	 thawed	
infected	 RBCs	 of	P. cynomolgi Berok	 K2,	 K4	 or	 K4-A7	 matured	 to	 majority	 late	
stage	parasites	over	40	h	using	MACS	LD	columns	 (Miltenyi	Biotech	Asia	Pacific	
Pte	Ltd).	A	MACS	LD	column	(Cat	no.	130042901,	Miltenyi	Biotec,)	was	affixed	to	
the	MidiMACS	 Separator	 (Cat	 no.	 130042302,	Miltenyi	 Biotec)	 and	 primed	with	
base	media.	The	parasite	culture	was	first	pelleted	by	centrifugation	at	1,800	rpm	
(627	rcf	xg)	for	5	min	at	RT,	washed	twice	with	base	medium	before	adjusting	to	
50%	haematocrit.	The	mixture	was	 layered	onto	 the	beads	of	MACS	LD	 column,	
and	 flow	 through	 containing	 uninfected	 RBCs	 and	 early	 stage	 parasites	 were	
retained	 in	a	50	mL	 falcon	tube	 for	continuous	culture.	The	column	was	washed	
thrice	with	3	mL	of	base	media.	After	the	flow	through	show	no	erythrocytes,	the	
LD	 column	 was	 removed	 from	 the	 MidiMACS	 Separator,	 and	 parasitized	
erythrocytes	magnetized	to	LD	column	were	eluted	into	a	15	mL	falcon	tube.	The	
eluted	 positive	 fraction	was	 defined	 as	 pelleted	 infected	 red	 blood	 cells	 (iRBCs)	
were	applied	to	invasion	inhibition	assays	(IIA),	or	could	be	routinely	applied	over	





pelleted,	 washed	 with	 base	 media,	 re-adjusted	 to	 50%	 hematocrit,	 and	 passed	
through	 a	 fresh	 LD	 column	 to	 minimise	 late-stage	 schizonts	 present	 in	 culture.	
This	 time	 round,	 the	 negative	 fraction	 instead	 of	 positive	 fraction	was	 retained	
and	 cultured	 at	 5	%	 hematocrit	 in	 complete	 growth	media	 at	 37°C	 in	 a	 sealed	
chamber	filled	with	tri-mix	gas.		
	






sorbitol	 (Cat	 no.	 S1876,	 Sigma-Aldrich)	 to	 give	 a	 final	 hematocrit	 of	 20%,	 and	





2.1.10 DNA extraction and Plasmodium spp PCR  
Plasmodium	spp	in	M.	fascicularis	donors	was	detected	by	PCR.	100	μL	of	heparin	
M.	 fascicularis	blood	 was	 aliquoted	 to	 an	 eppendorf	 tube	 and	 stored	 at	 -20	 °C.	
Samples	 were	 accumulated	 and	 thawed	 to	 perform	 DNA	 extraction.	 DNA	
extraction	was	performed	using	DNA	Blood	Mini	kit	(Cat	no.	51104,	Qiagen).	PCR	
methods	 adapted	 from	 Ta	 et	 al.,	 2014	 [94].	 Simply,	 Plasmodium	 spp	 primers–	
NewPLFshort	 CTATCAGCTTTTGATGTTAG	 and	 NewRevshort	
CCTTAACTTTCGTTCTTG	 were	 used	 to	 amplify	 18S	 ribosomal	 RNA	 consensus	




at	 94	 °C	 for	 4	 min	 followed	 by	 35	 cycles	 of	 denaturation	 at	 94	 °C	 for	 30	 s;	
annealing	at	55	°C	for	60	s,	extension	at	72	°C	for	60	s	followed	by	a	final	extension	




2.1.11 Screening M. fascicularis donors for continuous culture of P. 
cynomolgi  
To	 differentiate	 the	 ability	 of	 Macaque	 donors	 to	 sustain	 development	 of	 P.	
cynomolgi	Berok,	500	μL	of	complete	growth	media	was	placed	in	each	well	of	a	24	
well	plate,	and	seeded	with	12.5	μL	of	blood	(FM254,	FM255,	FM278,	and	FM284	






an	 ideal	 erythrocyte	 donor	 was	 selected,	 the	 culture	 was	 split	 to	 test	 various	
serum	 donors	 and	 incubated	 till	 “parasite	 crash”.	 Parasite	 crash	 is	 lab	 lingo	 to	
describe	 parasite	 death	 due	 to	 neglect	 in	 supplying	 fresh	 erythrocytes	 to	 highly	
replicating	 parasite	 culture.	 Serum	 donors	 which	 did	 not	 show	 parasite	 crash	
within	maximum	14	days	were	omitted	from	donor	list.	Finally,	donors	can	also	be	
ranked	 by	 serum	 clarity	 or	 pelleted	 blood	 volume	 in	 spun	 down	 serum	 and	
heparin	tubes	respectively	to	maximise	cost	and	value	to	experiments.		
	
2.1.12 Time lapse videomicroscopy P. cynomolgi Berok invasion  
A	petri	dish	with	a	borosciliate	film	for	imaging	was	made	by	the	University	glass	
blower	 and	 used	 for	 videomicroscopy.	 A	 3	 mL	mixed	 stage	 P.	 cynomolgi	Berok		
culture	at	10%	parasitaemia	and	0.7%	hematocrit	was	placed	 into	the	petri	dish	
and	 placed	 onto	 the	 stage	 of	 a	 pre-warmed	 chamber	 affixed	 to	 the	 confocal	
fluorescence	 FV1000	 microscope	 (Olympus).	 Cells	 were	 allowed	 to	 settle	 for	 5	
min,	 and	 an	 area	with	no	 overlapping	 cells	were	brought	 into	 focus.	 Time-lapse	

















2.2.1 Ethics for use of human clinical samples 







2.2.2 Reticulocyte enrichment, concentration of CD71+ cord blood 
reticulocytes 
After	delivery,	5	mL	of	 cord	blood	was	 immediately	 collected	 in	 lithium	heparin	
tubes	 from	 umbilical	 cords.	 The	 blood	 group	was	 determined	 using	 TransClone	
ABO	 antisera	 kit	 (Bio-Rad,	USA).	 The	 sample	was	 first	 transferred	 into	 a	 15	mL	
falcon	 tube	 and	 centrifuged	 at	 1,200	 rpm	 (279	 rcf	 xg)	 for	 5	 min	 at	 RT,	 then	
subjected	 to	 leukocyte	 removal	 according	 to	 Sriprawat	 et	 al.,	 2009.	 Briefly,	
supernatent	plasma	was	removed	after	centrifugation,	erythrocytes	were	washed	
using	 PBS,	 and	 layered	 on	 packed	 powdered	 cellulose	 (Sigma–Aldrich)	 column	
filtration	unit.	The	flow	through	was	pelleted,	and	volume	of	erythrocytes	adjusted	
to	50%	hematocrit	with	plain	McCoy’s	5A	medium	before	layering	on	a	6	mL	85%	
Isotonic	 Percoll	 cushion	 in	 a	 15	mL	 falcon	 tube.	 The	 tubes	 were	 centrifuged	 at	
2,491	 rpm	 (1,200	 rcf	 xg)	 for	 15	min	 at	 low	 acceleration	 and	 no	 deceleration	 to	
obtain	 an	 undisturbed	 band	 of	 enriched	 reticulocytes.	 The	 layer	 was	 carefully	
removed	using	a	Pasteur	pipette	and	washed	twice	in	plain	McCoy’s	5A	medium	to	
remove	 residual	 Percoll.	 To	 enrich	 for	 CD71+	 reticulocytes,	 the	 Percoll	 enriched	
reticulocytes	 were	 incubated	 with	 α-CD71	 antibody	 conjugated	 magnetic	
microbeads	 (Miltenyi	 Biotec)	 for	 20	 min	 on	 ice	 at	 50%	 hematocrit.	 Unbound	
antibodies	 were	 washed	 off	 with	 plain	 McCoy’s	 5A	 medium	 before	 placing	 it	
through	 a	 large	 selection	 (LS)	 column	 to	 obtain	 two	 fractions,	 CD71	 depleted	
(CD71-)	 and	CD71	enriched	 (CD71+)	 reticulocytes.	Both	 fractions	were	 stored	 in	
plain	McCoy’s	5A	medium	at	4	°C	up	to	one	month.	An	aliquot	from	both	fractions	
was	 stained	 with	 new	 methylene	 blue	 (Sigma–Aldrich)	 to	 determine	 purity.	 A	






2.2.3 P.vivax media components 
For	 P.	 vivax	 ex	 vivo	 culture,	a	 different	 medium	was	 used.	 The	base	 media	 was	
prepared	 with	 McCoy’s	 5A	 modified	 medium	 (Cat	 no.	 12330031,	 Gibco)	
supplemented	 with	 L-glutamine	 (Cat	 no.	 61870-036,	 Gibco)	 containing	 30	 mM	
HEPES	 (Cat	 no.	 H4034,	 Sigma-Aldrich),	 0.2%	 (w/v)	 D-glucose	 (Cat	 no.	 G7021,	
Sigma-Aldrich)	 and	 200	 µM	 hypoxanthine	 (Cat	 no.	 4010BC,	 Calbiochem).	 The	
complete	 P.	 vivax	 growth	 media	 constitutes	 of	 McCoy’s	 5A	 base	 media	
supplemented	with	20%	 (v/v)	 heat	 inactivated	human	 serum	 (AB+	or	B+	blood	
group).		
	






and	 diluted	 at	 1:50	 (v/v)	 with	 their	 respective	 complete	 growth	 media.	 The	
solution	was	mixed	well,	 and	 48	 μL	 aliquoted	 to	 each	well	 of	 a	 96	well	 round-
bottom	 plate	 (CoStar,	 Corning).	 For	 control	 antibodies,	 camelid	 α-Fy6	 2c3	 (gift	
from	Yves	Colins)		antibody	was	diluted	to	final	concentration	of	20	μg/mL,	and	α-
FyB	 IgG	 (Lorne)	 diluted	 13.5	 X	 (v/v)	 to	 target	 human	 and	 macaque	 DARC	
respectively.	 To	 determine	 inhibition	 activity	 of	 various	 α-DBP	 and	 α-RBP	
antibodies,	purified	rabbit	IgG	or	mouse	IgG	were	diluted	to	final	concentration	of	
200	μg/mL	per	well.	The	plate	was	then	 incubated	at	37	°C	 in	a	sealed	chamber	
filled	with	 tri-mix	 gas.	 Thin	 smears	were	 prepared	 at	 24	 h	 post	 incubation,	 and	
parasitaemia	 determined	 according	 to	 section	 2.1.6.	 %	 antibody	 inhibition	 was	
calculated	as	follows:	
	
100−  100 𝑋 ( 
% 𝑟𝑖𝑛𝑔𝑠 𝑜𝑓 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛




To	 determine	 reticulocyte	 preference	 of	P.	cynomolgi	Berok	merozoites	 via	 flow	
cytometry,	20	μL	of	host	cells	invaded	with	K2/GFP	was	placed	into	a	fresh	well	of	
a	 96-well	 U-bottom	 plate.	 Cells	 were	 incubated	 with	 50	 μL	 PBS	 containing	
CD240DCE	 conjugated	 to	Allophycocyanin	 (APC)	 (Cat	 no.	 130-104-864,	Miltenyi	
Biotec)	 at	 33X	 (v/v)	 dilution,	 and	 8	 μM	 of	 Hoechst	 34580	 (Thermo	 Fisher	
Scientific).	 Cells	 were	 incubated	 away	 from	 light	 for	 15	 min	 at	 RT.	 Excess	
antibodies	 and	 dye	 were	 removed	 by	 washing	 erythrocytes	 twice	 with	 PBS.	












GraphPad	PRISM	8	 (GraphPad	Software,	 Inc.,	CA,	 San	Diego,	CA,	USA).	To	assess	
the	 mean	 differences	 between	 groups	 (no	 inhibitor,	 α-Fy6	 2c3,	 and	 α-FyB	
antibodies)	of	 two	 independent	 factors	 (P.	vivax	and	P.	cynomolgi	Berok),	 a	 two-
way	ANOVA	analysis	was	conducted.		
	
2.2.6 Growth inhibition assay (GIA) 
To	characterize	the	extent	of	antibody	inhibition	on	P.	cynomolgi	Berok	K4-A7,	an	
extended	 growth	 inhibition	 assay	 (GIA)	 was	 adapted	 from	 Persson	 et	 al,.	2006	
[95].	 Parasite	 synchronisation	 was	 performed	 using	 a	 ‘quick	 and	 dirty’	 method	
instead	of	sorbitol.	Simply,	at	approximately	30	h	before	experiment,	P.	cynomolgi	
Berok	 culture	 was	 pelleted	 at	 2,400	 rpm	 (1,114	 rcf	 xg)	 for	 2	 min	 at	 RT,	 and	








and	 plated	 at	 0.63	mL/well	 in	 a	 96-well	 round-bottomed	 plate	 (Costar,	 USA).	
Antibodies	were	prepared	by	serial	dilution	at	1	mg/mL	(Well	no.	1).	Purified	IgG	
antibodies	were	not	diluted	if	stock	concentration	was	lower	than	100	μg/mL.	All	




well	 was	 aliquoted	 into	 a	 fresh	 round-bottomed	 plate,	 and	 stained	 with	 8	 μM	
Hoechst	 34580	 (Cat	 no.	 63493,	 Sigma)	 and	 150	 nM	 Mitotracker	 Deep	 Red	 FM	
Molecular	 Probes	 (Cat	 no.	 22426,	 Lab	 Supply),	 and	 acquired	 on	 Canto	 II	 flow	
cytometer	(Becton	Dickinson).	Plates	were	 incubated	with	dyes	for	20	min	away	
from	light	at	RT,	washed	twice	with	200	μL	PBS	each	time,	and	transferred	to	3	mL	
round	 bottom	 polystyrene	 tubes	 (Becton	 Dickinson)	 for	 acquisition.	 Hoechst	
34580	was	acquired	at	excitation	wavelength	of	392	nm	and	emission	wavelength	
of	440	nm,	and	Mitotracker	Deep	Red	was	acquired	at	excitation	wavelength	644	
nm	 and	 emission	 wavelength	 665	 nm	 using	 Violet	 laser.	 Data	 was	 analysed	 on	
Flowjo	 (Tree	 Star	 Inc)	 software,	 where	 single	 cells	 were	 gated,	 and	 values	
indicated	 in	 double	 positive	 population	 Hoechst	 34580+/Mitotracker	 Deep	 Red+	
were	exported	to	Excel	software.		
	
2.2.7 Statistical analysis (GIA) 
The	 inhibitory	 concentration	 at	 which	 antibody	 inhibition	 resulted	 in	 50%	
reduction	 to	PBS	 and	blank	 controls	 (IC50)	was	 calculated	using	 value	of	 double	
positive	 population	 in	 duplicated	 wells.	 First,	 values	 were	 transformed	 and	
normalized	using	GraphPad	PRISM	8.	Then,	 four	parameter	 logistic	model	or	 log	
(inhibitor)	 vs	 response	 –	 variable	 slope	was	 employed	 for	 dose-response	 curve	








Characterization of Duffy preference  





2.3.1 Phylogenetic tree construction 
Homologous	DBP	amino	acid	sequences	across	P.	vivax	strains	(Palo	Alto,	Simium,	
Belem,	Salvador	I	and	PvP01),	P.	vivax-like	Pvl01,	P.	cynomolgi	strains	(B,	M,	C	and	









2.3.2 Expression and purification of PvDBP and homologues 
Sequence	of	PvDBP	 from	P.	vivax	 strain	Salvador	 I	was	obtained	 from	PlasmoDB	
















































Server	 for	 HEK293	 EBNA1-6E	 cell	 expression	 system,	 and	 cloned	 into	 pTT3-
CD4d3+4	vector	(Cat	no.	68528,	Addgene)	using	NotI	and	AscI	restriction	enzymes	
via	 in-fusion	 cloning	 (Cat	 no.	 639650,	 Takara)	 to	 yield	 construct	 PvDBP194-521.	
Sequences	 of	 homologous	 proteins	 PcyDBP1	 and	 PcyDBP2	 from	 P.	 cynomolgi	
Berok	 were	 obtained	 from	 Tachibana	 et	 al	 (NCBI	 Accession	 number:	 JQ422035	





tag	 (CD4d3+4-His)	 at	 NH2	 terminus	 using	 HEK293	 EBNA1-6E	 cell	 expression	
system.	 Supernatent	 was	 collected	 6	 days	 after	 transfection,	 and	 centrifuged	 at	
3,938	rpm	(3,000	rcf	xg)	for	20	min	at	4	°C.	 	Protein	purification	was	performed	
using	 Ni-NTA	 resin	 (Thermo	 Fisher	 Scientific)	 according	 to	 manufacturer’s	
instructions.		PkDBPα	recombinant	protein	encompassing	amino	acids	200	to	536	
yield	construct	PkDBPα200-536	was	generated	according	to	Muh	et	al.,	2018.	Lastly,	
sequence	 encompassing	 amino	 acids	 121	 to	 747	 of	 PfEBA175	 was	 codon-
optimized	 using	 NetNGlyc	 1.0	 Server	 for	 HEK293	 EBNA1-6E	 cell	 expression	
system,	 and	 cloned	 into	 pTT3_MCS-linker-8xHis	 vector	 (Addgene)	 to	 yield	
construct	PfEBA175121-747.		
	
2.3.3 Expression and purification of human and macaque DARC 
Sequences	of	HsDARC	(Accession	number:	AAF02415.1)	and	MfDARC	(Accession	
number:	 NC_022272)	 were	 obtained	 from	 NCBI	 Database.	 HsDARC	 22FEDVW26,	
MfDARC	 22SEDLW26	 ,	 and	 MfDARC	 22S_DLW25	 constructs	 encoding	 HsDARC1-63,	
MfDARC1-62,	and	MfDARC1-61	spanning	amino	acid	residues	1	to	63,	1	to	62,	and	1	
to	61	 respectively	were	 codon-optimized	using	NetNGlyc	1.0	Server	 for	HEK293	
EBNA1-6E	 cell	 expression	 system,	 and	 cloned	 into	 pTT5	 expression	 vectors	
(Addgene).	 Each	 construct	 contained	 a	 Fc-fusion	 protein	 expressing	Fc	region	
(CH2	and	CH3	domains)	of	human	IgG1	heavy	chain	and	hinge	region	tag	(hIgG1-








2.3.4 In situ protein binding assay 
In	 situ	 protein	 binding	 assays	 were	 performed	 using	 5	 μg	 of	 PvDBP194-521,	
PcyDBP1180-504,	 and	 PcyDBP2184-507	 to	 HsDARC1-63,	MfDARC1-62,	 and	MfDARC1-61.	
Complex	 formation	 between	 parasitic	 and	 host	 proteins	 was	 determined	 by	
incubating	combination	of	human-macaque	DARC	recombinant	FC-tag	proteins	to	
100	μL	of	PBS.	 10	μL	was	 aliquoted	 to	 a	 fresh	 tube	with	2x	 SDS-PAGE	 reducing	
sample	 buffer	 (Thermo	 Fisher	 Scientific)	 labelled	 ‘Input’.	 Protein	 A-sepharose	
beads	(Thermo	Fisher	Scientific)	were	washed	three	times	in	PBS	and	spun	down	
at	2,000	rpm	(326	rcf	xg)	for	one	min,	and	30	μL	of	50%	(v/v)	beads	in	PBS	was	
added	 to	 samples	 and	 incubated	 for	 2	 h	 on	 rollers	 at	 RT.	 The	 beads	were	 spun	
down,	and	10	μl	aliquot	of	‘Unbound’	protein	was	placed	into	a	fresh	tube	with	2x	
SDS-PAGE	 reducing	 sample	 buffer,	 and	washed	 thrice	with	 PBS.	 Bound	proteins	
were	 eluted	 from	 beads	 by	 boiling	 for	 five	 minutes	 in	 2x	 SDS-PAGE	 reducing	
sample	 buffer	 and	 analysed	 on	 12%	 Bis-Tris	 gels	 (Invitrogen)	 in	 MOPS	 buffer	
(Invitrogen)	at	220	V	for	60	min	against	protein	ladder	(All	Blue,	Biorad).	Protein	
bands	 were	 visualized	 with	 Coomassie	 G-250	 stain	 (SimplyBlue	 SafeStain,	 Life	
Technologies).		
	
2.3.5 Homology modelling 
Three	 dimensional	 structure	 model	 of	 PcyDBP1	 was	 constructed	 by	 structural	
threading	 using	 algorithms	 in	 I-TASSER	 (Iterative	 Threading	 ASSEmbly	




TASSER	 server	 also	 automates	homology	modelling,	 sequence	 threading,	 and	 ab	








Characterization of reticulocyte preference  





2.4.1 Phylogenetic tree construction 
Homologous	RBP	amino	acid	sequences	across	P.	vivax	strains	(Belem,	Salvador	I	
and	 PvP01),	 P.	 vivax-like	 Pvl01,	 P.	 cynomolgi	 strains	 (Bastianellii,	 Mulligan,	
Cambodian	and	Berok	strains),	P.	knowlesi	(H	strain,	Pk1A,	and	Sarawak	isolates),	
P.	 inui	San	 Antonio	 I,	 P.	 ovale	 curtisi	GH1,	 and	P.	malariae	UG01	were	 identified	









2.4.2 Sequence alignment of PvRBP2b and PcyRBP homologues 
Sequence	of	PvRBP2b	from	P.	vivax	strain	Salvador	I	was	obtained	from	PlasmoDB	
Database	(Accession	number:	PVX_094255).	Synthetic	DNA	was	codon-optimized	
for	 expression	 in	 Shuttle	 T7	 E.	 coli	 (Life	 Technologies).	 The	 sequence	
encompassing	amino	acids	161	to	1,454	and	169	to	470	of	PvRBP2b	were	cloned	






























































was	 obtained	 from	 Tachibana	 et	 al.,	 2012	 (Accession	 number:	 JQ422039).	
Sequence	alignment	were	performed	using	ClustalW	with	MegAlign,	and	Snapgene	
Viewer.	For	PcyRBP2b,	the	sequence	encompassing	amino	acids	159	to	1453	and	
167	 to	 469	 was	 ordered	 in	 a	 pUC	 vector	 and	 cloned	 into	 pET32a(+)	 vector,	
yielding	 constructs	 Pcy2b159-1453,	 and	 Pcy2b167-469	 respectively.	 Paralogous	
proteins	 PcyRBP1a	 and	 PcyRBP1b	 were	 also	 obtained	 (Accession	 numbers:	
JQ422037	and	 JQ422038	respectively).	Sequence	encompassing	amino	acids	160	
to	 1181	 and	 137	 to	 1278,	 yielding	 constructs	 Pcy1a160-1181	 and	 Pcy1b137-1278		
respectively.	 These	 constructs	 allowed	 the	 expression	 of	 recombinant	 proteins	
fused	 to	bacterial	 thioredoxin,	8X	His-tag	and	 tobacco	etch	virus	 (TEV)	protease	
cleavage	site	at	NH2-terminus.	
	
2.4.3 Cloning of PcyRBP1a, PcyRBP1b, and PcyRBP2b into pET32a(+) 
expression vector 
Three	separate	DNA	plasmids	encompassing	PcyRBPs	stated	above	were	ordered	






and	 heat-inactivated	 for	 10	 min	 at	 65	 °C.	 1	 μL	 of	 ligated	 plasmids	 were	
transformed	into	Electromax	DH5α	E.	coli	(Invitrogen)	in	electroporation	cuvettes,	
recovered	with	 Yeast	 Tryptone	media	 and	 plated	 onto	 LB	 agar	 plates	with	 0.05	
mg/mL	Carbenicillin.	On	 the	 following	 day,	 positive	 clones	were	 amplified,	DNA	
purified	and	inserts	verified	via	sequencing.		
	
2.4.4 PcyRBP2b homology modelling 
A	 simulated	PcyRBP2b	 structure	modelled	 based	 on	 cryo-EM	PvRBP2b	 to	Homo	
sapiens	 (H.	 sapiens)	TfR1/Tf	 (PDB	 ID:	 6D05)	 was	 generated	 using	 Swiss-model	




quality	 control	 parameters	 were	 estimated	 and	 represented	 as	 Qmean	 Z-score.	





2.4.5 Site-directed mutagenesis of PcyRBP2b  
To	 induce	 site	 directed	 mutagenesis	 (SDM)	 using	 KaPa	 HiFi	 (Thermo	 Fisher	
Scientific)	within	PcyRBP2b/pET32a(+)	 vector,	 primers	 to	 generate	 ∆Ser590Arg	
and	∆Tyr604Ser	mutants	were	 first	designed	using	an	online	primer	 tool	 for	Q5	
SDM	(New	England	Biolabs).	Using	PCR,	 the	amplification	mixture	contained	 the	








(New	England	Biolabs).	 The	 plasmid	was	 purified	 using	DNA	 clean	 up	 kit	 (New	
England	 Biolabs)	 and	 sequenced	 at	 University	 of	 Otago	 sequencing	 facility	 to	
verify	presence	of	each	mutation.		
 
2.4.6 Expression and purification of recombinant parasitic proteins 
A	 1	 L	 Terrific	 Broth	was	 prepared	with	 2	 X	 Terrific	 Broth	 concentrate,	 Terrific	










for	 1	 h	 with	 shaking	 before	 induction	 with	 0.5	 mM	 isopropyl-β-D	
thiogalactopyranoside	(IPTG)	(Astral).	The	 flasks	were	 left	 to	 incubate	overnight	
at	16	°C	with	shaking.	The	next	day,	bacteria	was	harvested	by	centrifugation	at	




20	 °C	 freezer,	 then	 in	 tap	 water	 the	 following	 morning.	 The	 pellet	 was	
resuspended	with	freezing	buffer	to	approximately	100	mL	on	ice,	and	0.5	mg/mL	
DNase	 and	 1.0	 mg/mL	 lysozyme	 (Sigma)	 added	 to	 suspension.	 Cells	 were	
sonicated	 on	 ice	 at	 30%	 amplitude	 with	 pulsation	 every	 30	 s	 for	 20	 min.	 The	
mixture	 was	 swirled	 manually	 between	 pulses	 to	 distribute	 heat	 generated	 by	
sonication.	 The	 sonicated	 solution	 was	 transferred	 to	 round	 bottom	 tubes	 and	
centrifuged	at	17,252	rpm	(30,000	rcf	xg)	(Beckman	Coulter)	for	45	min	at	4	°C.	To	
remove	 precipitate,	 the	 supernatant	 was	 passed	 through	 a	 0.22	 μM	 filter,	 and	
applied	on	a	5	mL	HisTrap	HP	column	(GE	Healthcare)	connected	to	a	bench-top	
peristaltic	 pump.	 Unbound	 material	 was	 removed	 with	 10	 column	 volumes	 of	
washing	buffer	 (50	mM	Tris·HCl,	 pH	7.5,	 500	mM	NaCl,	 10%	 (vol/vol)	 glycerol)	
with	10	mM	imidazole.	Bound	protein	was	eluted	using	washing	buffer	with	300	
mM	 imidazole.	TEV	protease	was	added	 to	protein	solution	and	 transferred	 into	
snakeskin	 of	 10	 kDa	MWCO	 and	 dialysed	 overnight	 in	 buffer	 containing	 20	mM	
Hepes,	 pH	 7.5,	 200mM	 NaCl.	 The	 dialysed	 sample	 was	 recovered	 the	 following	
morning	and	filtered	before	passing	it	through	the	HisTrap	HP	column	to	remove	
unprocessed	protein.	The	collected	flow-through	was	concentrated	to	4.5	mL	and	
injected	 onto	 a	 S200	 Superdex	 16/600	 size	 exclusion	 column	 (GE	 Healthcare)	










2.4.7 Expression and purification of human and macaque transferrin 
receptor 1 
HsTfR1	 and	MfTfR1	 constructs	 encoding	 the	 soluble	 ectodomain	 of	 transferrin	
receptor	 1	 spanning	 amino	 acid	 residues	 121	 to	 760	 were	 purchased	 from	
Addgene	 in	 pAcGP67A	 expression	 vectors	 (Pharmingen).	 TfR1	 Baculovirus	 was	
expressed	by	transfecting	pACGP67A/TfR1	into	Sf21	cells	(Life	Technologies)	with	
Cellfectin,	 and	 cultured	 in	 Insect-XPRESS™	 Protein-free	 Insect	 Cell	 Medium	
supplemented	 with	 L-glutamine	 (Lonza).	 As	 E.	 coli	 cannot	 express	 functional	
multi-domain	mammalian	proteins,	TfR1	was	induced	by	inoculating	Sf21	cells	at	
1	 x	 106	 cells/ml	 with	 third	 passage	 (P3)	 of	 Baculovirus	 for	 three	 days.	 Media	
supernatant	was	collected	by	centrifugation	at	4,950	rpm	(2,000	rcf	xg)	for	20	min	
and	 concentrated	 by	 tangential	 flow	 filtration	 device	 with	 10	 kDa	 molecular	
weight	 cut-off	 casette	 (Millipore).	 Concentrated	 supernatants	 were	 dialyzed	 in	
buffer	 containing	 20	 mM	 TrisHCl	 pH	 7.5	 and	 300	 mM	 NaCl	 overnight.	 After	
dialysis,	 protein	 was	 captured	 using	 Ni-NTA	 chromatography.	 The	 dialyzed	
sample	was	 loaded	onto	5	mL	HisTrap	 column	 (GE	Healthcare)	pre-equilibrated	
with	dialysis	buffer.	Unbound	material	was	washed	away	with	10	column	volumes	
of	dialysis	buffer	 supplemented	with	20	mM	 imidazole.	Protein	was	eluted	 from	
the	 column	 with	 dialysis	 buffer	 supplemented	 with	 300	 mM	 imidazole.	 The	





2.4.8 Immunization of rabbits for antibody production 
α-PcyRBP1a160-1181,	 	 α-PcyRBP1b137-1278	 ,	 and	 α-PcyRBP2b159-1453	 polyclonal	
antibodies	 were	 produced	 at	 the	 Walter	 and	 Eliza	 Hall	 Institute	 Monoclonal	
Antibody	 Facility	 (Bundoora,	 Australia).	 Three	 rabbits	 were	 immunized	 three	
times,	and	each	time	with	90	μg	of	recombinant	PcyRBP1a160-1181,	PcyRBP1b137-1278		
and	150	μg	of	PcyRBP2b159-1453	proteins.	The	first	immunization	was	administered	
with	 complete	 Freund’s	 adjuvant	 and	 two	 others	 with	 incomplete	 Freund’s	






2.4.9 Reticulocyte enrichment for RBC binding assay 
500	mL	of	whole	blood	(Australian	Red	Cross)	was	filtered	with	RC	high	efficiency	








made	 and	 %	 of	 enrichment	 determined	 with	 a	 light	 microscope.	 Reticulocyte	
enriched	blood	was	stored	in	RPMI	wash	buffer	(Gibco)	at	4	°C	until	further	usage.	
 
2.4.10 Flow cytometry based red blood cell binding assay 




respective	 primary	 polyclonal	 antibodies	 (0.0125	 mg/mL)	 were	 added	 and	
incubated	on	rollers	for	1	hour	at	RT.	Unbound	primary	antibodies	were	washed	
with	PBS	and	centrifuged	at	4,950	rpm	(2,000	rcf	xg)	for	1	min,	and	the	pellet	was	




and	 pelleted	 RBC	 was	 resuspended	 with	 200	 μL	 HTPBS	 and	 analysed	 on	
FACSCalibur	 flow	cytometer	 (BD	Biosciences).	50,000	events	were	recorded	and	
results	 analysed	with	 FlowJo	 software	 (Tree	 Star).	%	binding	was	 calculated	 by	


















was	 used	 to	 stop	 the	 reaction.	 Absorbance	 was	 read	 at	 405	 nm	 using	 a	 plate	
reader	(Perkin	Elmer	Life	Sciences).	
	
2.4.12 Co-immunoprecipitation assay  
Co-immunoprecipitation	assays	were	performed	using	5	μg	of	either	PvRBP2b161-
1454,	 PcyRBP2b159-1453,	 	 PcyRBP1a160-1181,	 PcyRBP1b137-1278	 	 to	 either	 human,	 or	
cynomolgus	 macaque	 TfR1	 and	 Transferrin	 proteins.	 Human	 apo-transferrin	
protein	 was	 purified	 from	 human	 serum	 (Cat	 no.	 T4382,	 Sigma-Aldrich)	 and	










buffer,	 and	 washed	 thrice	 with	 PBS.	 Primary	 antibody	 and	 associated	 proteins	





for	 60	 min.	 Protein	 bands	 were	 visualized	 with	 Coomassie	 G-250	 stain	
(SimplyBlue	SafeStain,	Life	Technologies).	
 
2.4.13 Western blot sample preparation 
Four	 samples	 were	 collected	 to	 determine	 binding	 of	 α-PcyRBP1a160-1181,	 	 α-
PcyRBP1b137-1278	,	and	α-PcyRBP2b159-1453	polyclonal	antibodies	to	native	protein.	
The	 samples	 include	 controls	 uninfected	 M.	 fascicularis	 erythrocytes	 and	 P.	
cynomolgi	 complete	 growth	 media,	 and	 test	 samples	 K4-A7	 parasitized	 M.	
fascicularis	 erythrocytes	 and	 culture	 growth	 media	 supernatent.	 5	μL	 of	 fresh	
parasite	pellet	and	50	μL	of	culture	supernatent	aliquots	were	diluted	in	95	μL	and	
50	μL	2X	reducing	buffer	respectively.	To	examine	expression	of	RBP	proteins	was	
determined	every	6	h	starting	 from	majority	 late-trophozoite	stage	 (T0).	Briefly,	





and	 the	 infected	 red	 blood	 cell	 pellet	 transferred	 to	 fresh	 tube.	 The	 tubes	were	
collected	and	stored	at	-80	°C.	Samples	were	collected	every	6	h	for	10	time	points.	




2.4.14 Western blot analysis 
The	samples	were	loaded	in	triplicate	and	separated	on	4-12%	SDS-PAGE	at	80	V	
for	20	min,	 then	180	V	 for	1	h.	Membranes	were	 transferred	onto	nitrocellulose	












Tween/PBS	 for	 5	min	 to	 remove	 unbound	 antibodies	 and	 visualized	 at	 700	 nm	
wavelength	 on	 Odyssey	 infrared	 imaging	 system	 (LI-COR	 Bioscience)	 using	
Odyssey	software	(LI-COR	Bioscience).	
	
2.4.15 Immunofluorescence assay  
1	μL	of	MACS	purified	schizont	K4-A7	parasitized	M.	fascicularis	erythrocytes	was	
seeded	 into	 each	well	 of	 a	 10	well-coverslip	 and	 air-dried	 overnight.	 The	 slides	
was	 fixed	 and	 permeabilized	with	 -20	 °C	 acetone	 for	 1	 h.	 The	 slides	were	 then	
washed	thrice	in	PBS	and	blocked	with	1%	BSA/PBS	(w/v)	for	2h	at	RT.	To	stain	
for	PcyRBP1a,	PcyRBP1b	or	PcyRBP2b,	each	well	was	incubated	with	solution	of	α-	
PcyRBP1a160-1181,	 α-	 PcyRBP1b137-1278,	 or	 α-	 PcyRBP2b159-1453	 in	 1%	 BSA/PBS	
(w/v)	for	1	h	in	a	humid	chamber	at	37	°C.	The	wells	were	gently	washed	with	1%	




mm	 coverslip,	 left	 to	 hardened	 at	 RT	 for	 2	 h,	 and	 viewed	 under	 fluorescence	
confocal	microscope	(Olympus).		
	
2.4.16 Fixed cell imaging  
Coverslip	mounted	glass	slides	were	observed	using	Olympus	Fluorview	FV2000	
confocal	 laser	 scanning	 microscope	 and	 the	 images	 captured	 with	 Olympus	
Workspace	software	(Olympus).	Alexa	546-conjugated	antibodies	and	DAPI	were	














2.5.1 Rhesus factor – RHD and RHCE blood group (Macaque) 
The	R-C-E-F	system	in	MNS	blood	group	were	undetected	on	erythrocytes	of	old	
world	primates	 such	as	Macaca.	To	verify	 this	 genotyping,	RhD	and	RhCE	genes	
were	 amplified	 in	 M.	 fascicularis	 DNA	 with	 primers	 and	 amplification	 steps	
according	to	Reid	et	al.,	2000.		
	




using	 DNA	 blood	 extraction	 kit	 (Qiagen).	 PCR	 was	 conducted	 with	 primers	
amplifying	SMIM1	regulatory	rs1175550	SNP	region.	Primers	were	adapted	from	
Christophersen	 et	 al.,	 2017,	 with	 slight	 modifications.	 Reverse	 primer	 1	 was	
corrected	 to	 5'-	 CTCTGAGGCTGCTGTTAGGAG-3'	 and	 reverse	 primer	 2	 to	 5'-
GGTCTGTCGCCTGACTTAACA-3'	[96].	Amplified	DNA	was	separated	on	a	1%	TAE	
gel,	 purified,	 and	 sequenced	 at	 the	 University	 of	 Otago	 Sequencing	 facility.	 For	
RNA	 extraction,	 1	 mL	 of	 Trizol	 was	 placed	 into	 each	 cryovial.	 The	 tubes	 were	
gently	inverted	and	contents	transferred	into	15	mL	falcon	tubes.	The	sample	was	




was	 accelerated	 by	 incubating	 tubes	 overnight	 at	 -20	 °C.	 The	 tubes	 were	
centrifuged	at	3,000	rpm	(735	rcf	xg)	for	1.5	h	at	4	°C,	and	supernatent	removed.	
The	pellet	was	washed	with	10	mL	of	70%	Analytical	Grade	Ethanol/Milli-Q,	and	
incubated	on	 ice	 for	10	min.	The	pellet	was	 retrieved	again	by	 centrifugation	at	
3,000	rpm	(735	rcf	xg)	for	45	min	at	4	°C.	Supernatent	was	removed,	and	pellet	air	
dried.	 The	 RNA	was	 reconstituted	 in	 10	 μL	 of	 RNAse	 free	water.	 The	 yield	 and	
purity	 of	 RNA	 samples	were	 determined	 using	 a	 spectrophotometer	 (NanoDrop	
ND-1000	 V3.0.1,	 NanoDrop®	 technologies).	Real-time	 reverse	 transcription	












2.6.1 High pressure freezing  
A	 majority	 late-stage	 parasite	 P.	 cynomolgi	 Berok	 culture	 of	 K2	 or	 K4-A7	 was	
enriched	according	to	Section	2.1.8.	The	eluted	volume	was	diluted	1:1	(v/v)	with	




carriers	 and	 frozen	 via	 high	 pressure	 freezer	 with	 rapid	 transfer	 system	 EM	
PACT2	(Leica).		
	
2.6.2 Epoxy embedding  
Samples	were	 transferred	 to	 cryo-substitution	 solution	 (0.125%	glutaraldehyde,	
0.1%	 osmium	 tetroxide,	 0.2%	 uranyl	 acetate,	 and	 0.375%	 H2O	 in	 acetone)	 and	
incubated	 at	 −90 °C	 for	 96 h	 in	 an	 automated	 freeze	 substitution	 device	 (AFS2,	
Leica	microsystems).	Samples	were	warmed	in	a	step-wise	manner	at	−50 °C	over	
8	h,	incubated	for	1	h	at	−50 °C,	then	gradually	warmed	to	−25 °C,	incubated	for	12	
h,	 then	warmed	 to	0 °C.	The	samples	were	allowed	 to	 incubate	at	0 °C	 for	1	h	 in	
cryo-substitution	 solution,	 and	 washed	 thrice	 in	 acetone	 for	 15	 minutes	 each.	
Samples	 were	 then	 put	 through	 three	 dilutions	 of	 epoxy	 resin	 (EMBED	 812	




2.6.3 Single section transmission electron micrographs  
For	single	sections,	the	embedded	samples	were	sectioned	at	80	to	100 nm	using	a	








2.6.4 Tomograms  
The	 embedded	 expoxy	 sections	 were	 sectioned	 into	 250 nm	 blocks	 and	 placed	
onto	 a	 copper	 mesh	 grid,	 and	 examined	 on	 transmission	 electron	 microscope	
(2200FS,	 JEOL	 Ltd).	 Tilt	 series	 were	 collected	 from	 tilt	 range	 of	 ±65°	 in	 1°	
increments	 at	 6,000	 X	 magnification	 using	 open-source	 serialEM	 software	
(https://bio3d.colorado.edu/SerialEM/).	 An	 energy	 filter	 was	 used	 to	 improve	
contrast	 by	 zero-loss	 filtering.	 Tomographic	 reconstructed	 montages	 were	






Preamble to Results 
The	 results	 presented	 will	 follow	 the	 order	 in	 Methodology	 where	
Methodology	 Chapters	 2.1	 and	 2.2	 were	 combined	 to	 Results	 Chapter	 3	 as	 the	
concept	 of	 P.	 cynomolgi	Berok	 adaptation	 to	 human	 erythrocytes	 overlaps	 with	
















3.1 P. cynomolgi Berok culture at University of Otago 
A	 M.	 fascicularis	 macaque	 inoculated	 with	 P.	 cynomolgi	 Berok	 strain	
cryopreserved	 in	Aotus	trivirgatus	erythrocytes	 showed	proliferating	parasites	4	
weeks	after	inoculation	and	was	named	Berok	1	(K1)	(Figure	3.1).	K1	was	allowed	
to	proliferate,	 ring	 stages	 cryopreserved,	 and	 re-inoculated	 to	2	other	macaques	
K2	and	K3.	Both	K2	and	K3	showed	peripheral	blood	parasites	a	 few	days	after,	
and	 parasites	 were	 subjected	 to	 in	 vitro	 culture	 using	 methods	 adapted	 from	
Nguyen	et	al,.	1981	[64].	K3	showed	sub-optimal	growth	 in	vitro,	and	K2	showed	
continuous	robust	growth	for	a	year.	After	1	year,	the	parasite	was	labelled	as	K4	
where	 limiting	 dilution	 on	 K4	 obtained	 single	 clone,	 K4-A7,	 for	 whole	 genome	
sequencing.	 The	 parasites	 were	 imported	 from	 the	 National	 University	 of	
Singapore	to	University	of	Otago.		
	
To	 source	 fresh	 M.	 fascicularis	 erythrocytes	 for	 continuous	 culture	 at	
University	 of	 Otago,	 we	 enquired	 the	 cost,	 veterinary	 status,	 and	 delivery	 of	
peripheral	 blood	 from	 various	 non-human	 primate	 (NHP)	 facilities.	 Amongst	
facilities	 enquired,	 pooled	 blood	 from	 Vietnam	 macaques	 contaminated	 with	
Plasmodium	spp	was	unsuitable	 in	assays,	whereas	 the	Monash	Animal	Research	
Platform	 (MARP)	 in	 Australia	 provided	 well	 labelled	 samples	 and	 fulfilled	









Figure	 3.1	 Flow	 diagram	 for	 re-establishing	 and	 re-locating	 continuous	
culture	of	P.	cynomolgi	Berok.	
A	schematic	diagram	of	the	successful	adaptation	of	P.	cynomolgi	Berok	to	in	vitro	
continuous	 culture.	 The	 upper	 timeline	 shows	 re-establishment	 of	 continuous	
culture	and	lower	timeline	shows	re-location	of	cryopreserved	K2,	K4,	and	K4-A7	
vials	 from	 National	 University	 of	 Singapore,	 Singapore	 to	 University	 of	 Otago,	
Otago,	New	Zealand.	The	stocks	were	 thawed	and	stabilized	 in	 reliable	macaque	
donor	 RBC	 and	 serum.	 Naïve	 M.	 fascicularis	 peripheral	 blood	 were	 sourced,	
documentation	 approved	 and	 screening	 of	 macaques	 were	 initiated.	 Once	 good	
donors	 were	 identified,	 laboratory	 stocks	 were	 made	 for	 phenotypic	 and	
genotypic	 characterisation.	 Invasion	 biology	 to	 Chapter	 3,	 parasitic	 protein	
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3.2 Screening M. fascicularis macaques for Plasmodium spp 









(A)	 Agarose	 gel	 electrophoresis	 of	 Plasmodium	 spp	 PCR	 to	 determine	 existing	
malaria	 infection.	 Samples	 tested	were	negative	water	 control	 (lane	2),	 genomic	
DNA	 isolated	 from	P.	cynomolgi	K2	culture	(lane	3),	 four	M.	fascicularis	macaque	
donors	 from	 MARP	 (FM254,	 FM255,	 FM278,	 and	 FM284	 from	 lanes	 4	 to	 7	
respectively),	 and	pooled	M.	fascicularis	macaque	donors	 from	Vietnam	(lane	8).	
(B)	 In	 a	 separate	 PCR,	 samples	 tested	 were	 negative	 water	 control	 (lane	 2),	






3.3 Screening MARP M. fascicularis macaques for development of P. 






culture	 was	 initiated	 in	 #2424,	 then	 diluted	 at	 ratio	 Parasites:	 RBC	 1:5	 on	 the	
following	day	(Day	1)	using	uninfected	MARP	and	#2424	RBC.	The	cultures	were	
diluted	 further	 on	 day	 4	 (1:1),	 day	 6	 (1:5)	 and	 day	 10	 (1:1).	 All	 cultures	 were	




Tracking	of	P.	cynomolgi	Berok	parasitaemia	 (%	Parasites)	 in	 five	M.	fascicularis	












3.4 Live cell imaging of P. cynomolgi Berok K4 merozoite invasion 
As	 part	 of	 our	 efforts	 to	 select	 the	 best	 donor	 host	 cells,	 we	 conducted	




going	 K4	 in	 vitro	 culture	 was	 imaged	 continuously	 for	 60	 min	 using	 Olympus	
FV2000	confocal	microscope.	 	A	 time	series	of	 images	captured	every	10	s	were	
cropped	 to	 single	 cell	 and	placed	 into	 an	 image	 sequence.	We	observed	 that	K4	
merozoites	can	invade	both	naïve	and	parasitized	erythrocytes,	where	merozoite	
invasion	consists	of	anterior	end	attachment	to	erythrocyte	membrane	triggering	
























3.5 Purification of late-stage K4 parasites 
To	 obtain	 an	 enriched	 fraction	 of	 infected	 RBCs	 for	 invasion	 inhibition	
assays,	 ex	 vivo	 P.	 vivax	matured	 to	 schizont	 stage	 first	 use	 trypsin	 to	 reduce	
rosettes	 then	 purified	 via	 Percoll	 gradient	 centrifugation	 (trypsin-Percoll)	 [69].	
However,	 recent	development	 in	 tools	have	allowed	 researchers	 to	 adopt	use	of	
MACS	 LD	 column	 to	 isolate	 late-stage	 parasites	 by	 magnetising	 intracellular	
hemozoin	 to	 a	 magnetized	 column,	 and	 elute	 by	 moving	 column	 away	 from	
magnet.	 Even	 though	 previous	 publication	 examined	 P.	 cynomolgi	 Bastianellii	
invasion	 inhibition	 assays	 using	 magnetically	 purified	 schizonts	 [65],	 it	 is	 not	





schizonts	 following	 Percoll	 density	 centrifugation	 (Figure	 3.5A).	 We	 skipped	
trypsin	 treatment,	 and	 divided	 K4	 culture	 between	 Percoll	 and	MACS	methods.	
Our	 preliminary	 data	 showed	 that	 Percoll	 enrichment	 did	 yield	 a	 band	 of	
erythrocytes,	but	this	enriched	fraction	showed	lysed	K4	schizonts	under	Wright’s	









(A)	 Untreated	 and	 trypsin-treated	 K4	 cultures	 subjected	 to	 Percoll	 density	
centrifugation,	 and	 enriched	 a	 band	 of	 infected	 erythrocytes	 (black	 dotted	 box).	
(B)	Late-stage	K4	parasites	subjected	 to	Percoll	density	centrifugation	(left)	and	








3.6 Human host tropism in erythrocytic P. cynomolgi Berok K2 
merozoites 
To	 investigate	 if	 P.	 cynomolgi	 Berok	 merozoites	 also	 prefer	 immature	
reticulocytes	 like	P.	cynomolgi	Bastianellii	[65],	separated	 fractions	of	CD71+	and	
CD71-	cord	blood	reticulocytes	were	subjected	to	enriched	P.	cynomolgi	Berok	K2	
late-stage	 parasites	 for	 24	 h.	 A	 3.4	 fold	 increase	 was	 observed	 in	 CD71+	
reticulocytes	than	CD71-	(p	<	0.05),	with	a	mean	percentage	of	healthy	ring	stage	
parasites	at	0.93%	and	0.27%	respectively	(Figure	3.6).	Wright’s	stain	of	culture	





(Left)	 Dot	 plot	 indicates	 mean	 percentage	 of	 healthy	 ring	 stage	 parasites	 with	
standard	 deviation	 shown	 as	 error	 bars.	 Each	 dot	 represents	 one	 biological	
reticulocyte	 sample.	 Error	 bars	 represent	 mean	 ±	 standard	 deviation	 of	 6	
























3.7 P. cynomolgi Berok K2 culture adaptation to human erythrocytes 
Ideally,	humanizing	P.	cynomolgi	Berok	would	reduce	 the	need	 for	animal	
experimentation,	 and	 extend	 our	 understanding	 towards	 P.	 cynomolgi	 zoonotic	
transmission.	Although	 in	vitro	P.	cynomolgi	Berok	culture	 could	be	 sustained	 in	
media	 supplemented	 with	 either	 simian	 serum,	 human	 serum	 or	 fetal	 bovine	
serum	(FBS),	host	cells	for	in	vitro	propagation	is	only	available	to	M.	fascicularis	
and	 M.	 mulatta	 erythrocytes.	 In	 related	 monkey	 malaria,	 P.	 knowlesi,	 in	 vitro	
adaptation	 from	 simian	 to	 human	 red	blood	 cells	 (RBCs)	was	 achieved	over	 a	 9	
month	period	[89].		
	
To	 test	 RBC	 and	 serum	 conditions	 to	 humanize	 P.	 cynomolgi	 Berok,	
parasites	 were	 grown	 in	 human	 RBCs	 using	 media	 supplemented	 with	 20%	
human	 serum	 (Figure	 3.7A),	 human	 RBCs	 in	 media	 supplemented	 with	 20%	
simian	 serum/FBS	 at	 a	 1:1	 ratio	 (Figure	 3.7B),	 and	 simian	 RBCs	 in	 media	
supplemented	 with	 20%	 human	 serum	 (Figure	 3.7C).	 At	 5	 days	 post	 culture,	
Wright’s	 stain	 show	 loss	 of	 chromatin	 in	 merozoites	 grown	 in	 human	 RBCs	
supplemented	with	20%	human	serum.	Merozoites	retained	chromatin	in	human	
RBCs	 in	 with	 media	 supplemented	 with	 full	 or	 partial	 simian	 serum.	 When	
cultures	 were	 subjected	 to	 long	 term	 adaptation,	 parasites	 cultured	 in	 human	
RBCs	 did	 not	 sustain	more	 than	 2	weeks	 post	 culture,	 whereas	 simian	 RBCs	 in	








P.	 cynomolgi	Berok	 schizonts	 cultured	with	 various	 RBCs	 and	 serum	 conditions	
and	 stained	 with	 Giemsa	 Wright’s	 stain	 at	 D5	 post	 culture.	 Eosin	 in	 Giemsa	
Wright’s	 stain	 stains	 parasite’s	 chromatin	 pink	 or	 purple,	 and	 methylene	 blue	










3.8 Duffy preference in P. cynomolgi Berok K2  
To	determine	 if	 invasion	 to	P.	cynomolgi	Berok	 is	 duffy	dependent	 like	P.	






(Figure	3.8).	 In	 reticulocytes	 incubated	with	α-FyB	antibodies,	%	rings	was	1.88	
and	 52.75	 times	 lower	 than	 no	 antibody	 control	 for	 P.	 vivax	 and	 P.	 cynomolgi	
Berok	K2	respectively.	When	normalized	to	no	inhibitor	control,	P.	vivax	infected	
reticulocytes	 inhibited	 with	 DARC	 antibodies	 showed	 significant	 percentage	 of	
inhibition	 (%	 Inhibition)	 (α-Fy6	 2c3	 p	 <0.0001;	 α-FyB	 p	 =	 0.0003),	whereas	 P.	











mean	 percentage	 of	 healthy	 rings	 with	 error	 bars	 showing	 standard	 deviation.	
Percentage	of	healthy	ring	stage	parasites	(%	Rings)	between	P.	cynomolgi	and	P.	
vivax	inhibition	invasion	assay.	(Right)	Normalized	data	to	indicate	percentage	of	































































3.9 Invasion inhibition assay 
Invasion	 inhibition	 assay	 was	 explored	 further	 using	 antibodies	 and	
peptides	from	collaborators	to	target	parasitic	ligands	and	host	receptors.	Various	
invasion	proteins	of	P.	vivax,	such	 as	merozoite	 surface	protein	 (PvMSP)	 (Figure	
3.9A),	reticulocyte	binding	protein	2b	(PvRBP2b)	(Figure	3.9B),	and	host	antigen	
SMIM1,	 a	 regulatory	 element	 of	 Vel	 blood	 group	 (Figure	 3.9C)	were	 tested.	 The	
experiment	was	 conducted	with	 CD71+	 cord	 blood	 reticulocytes	 incubated	with	
enriched	 P.	 vivax	 or	 P.	 cynomolgi	K2	 late-stage	 parasites.	 Our	 preliminary	 data	
explored	 PvMSP,	 PvRBP2b	 and	 SMIM1	 antibodies	 and	 peptides,	 and	 show	 only	
peptides	PvMSP1P	P3	and	PvMSP1P	P6	to	successfully	inhibit	 invasion	in	both	P.	












Figure	 3.9	 Inhibition	 invasion	 assay	 targets	 PvMSP,	 PvRBP2b	 and	 host	
SMIM1.			
CD71+	 reticulocytes	 were	 inhibited	 with	 antibodies	 or	 peptides	 raised	 towards	
conserved	parasite	ligand	or	host	SMIM1	recombinant	proteins	and	examined	in	P.	
vivax	and	P.	cynomolgi	inhibition	invasion	assay	(IIA).	Antibodies	were	annotated	
with	 symbol	 α.	 Positive	 control	 is	 shown	 as	 no	 antibody	 control.	 Experimental	








































































































































































































































































































antibodies	 and	 peptides.	 (B)	 IIA	 using	PvRBP2b	mouse	 and	 human	monoclonal	
antibodies.	(C)	 IIA	 using	 antibodies	 and	 peptides	 raised	 against	 host	 regulatory	
element	 SMIM1.	 Dot	 plot	 indicates	 mean	 percentage	 inhibition	 (%	 Inhibition)	
from	 duplicate	 experiments	 with	 error	 bars	 showing	 standard	 deviation.	 Each	







3.10 Growth inhibition assay with DBP and RBP antibodies 
Due	to	limited	parasite	multiplication	in	ex	vivo	P.	vivax,	we	took	advantage	
of	 K4’s	 robust	 growth	 and	 explored	 antibody	 inhibition	 using	 growth	 inhibition	
assay.	Using	flow	cytometry,	viable	parasites	were	determined	in	double	positive	
Mitotracker	 Deep	 Red+/	 Hoechst	 34580+	 population	 at	 4	 days	 post	 incubation.	
Using	 Prism	 8,	 percentage	 of	 viable	 parasites	 were	 normalized	 and	 plotted	
separately	 for	 antibody	 stock	 concentrations	 lower	 than	 100	 μg/ml,	 and	 non-
linear	regression	curves	fitted	accordingly.		
	
Monoclonal	 antibodies	 targeting	 PvDBP	 region	 II	 domain	 α-3D10,	 α-2H2	
(Figure	 3.10A),	 α-2C6	 (Figure	 3.10B),	 α-2D10	 (Figure	 3.10C),	 α-3A4	 (Figure	
3.10D),	and	α-3C9	(Figure	3.10E)	were	examined	at	serial	dilutions.	The	estimated	
IC50	 values	 were	 plotted	 using	 Prism,	 and	 one-way	 Anova	 statistical	 analysis	
performed	 (p	=	0.008)	 (Figure	3.10F).	Our	data	 shows	 that	PvDBP	α-2C6	 (mean	
7.52	 μg/ml)	 inhibited	 parasite	 growth	 at	 three	 times	 lower	 concentration	 than	
DARC	 antibody	 α-Fy6	 2c3	 (mean	 23.2	 μg/ml).	 The	mean	 IC50	 for	 other	 PvDBP	
antibodies	 are	 35.07	 μg/ml	 (α-3D10),	 28.42	 μg/ml	 (α-2H2),	 16.58	 μg/ml	 (α-
2D10),	23.75	μg/ml	(α-3A4),	and	23.65	μg/ml	(α-3C9).	
	
PvRBP	polyclonal	 antibodies	 targeting	N-terminus	 region	of	PvRBP	which	
includes,	 α-PvRBP1a	 (α-Pv1a),	 α-PvRBP1b	 (α-Pv1b),	 α-PvRBP2a	 (α-Pv2a),	 α-
PvRBP2b	 (α-Pv2b),	 α-PvRBP2c	 (α-Pv2c),	 and	 α-PvRBP2-P2	 (α-Pv2-P2),	 were	
examined	at	single	concentration	of	200	μg/mL.	Our	preliminary	data	shows	that	
PvRBP	antibodies	do	not	inhibit	growth	of	K4	culture	in	vitro	with	varying	results	
in	 α-Pv1a	 (Figure	 3.10G).	 Polyclonal	 antibodies	 targeting	 N-terminus	 region	 of	
PcyRBP	 includes	 α-PcyRBP1a	 (α-Pcy1a),	 α-PcyRBP1b	 (α-Pcy1b),	 α-PcyRBP2b	 (α-
Pcy2b)	 were	 examined	 at	 serial	 dilutions	 from	 100	 μg/ml.	 No	 inhibition	 was	














Mitotracker	 Far	 Red+/H34580+).	 Experimental	 controls	 were	 α-Fy6	 2c3	 and	 α-
FyB.	Non-linear	regression	curve	fit	of	(A)	α-Fy6	2c3,	α-FyB,	α-3D10,	α-2H2,	(B)	α-
2C6,	(C)	α-2D10,	(D)	α-3A4,	and	(E)	α-3C9.	Curves	shown	are	a	representation	of	
N=	 3	 biological	 replicates.	 (F)	 Bar	 graph	 shows	 mean	 IC50	 values	 of	 PvDBP	
monoclonal	 antibodies	 with	 error	 bars	 showing	 standard	 deviation.	 Statistical	
results	from	one-way	ANOVA	shown	in	a	table	below	graph.	Data	points	represent	
biological	 replicates.	 (G)	 Bar	 graph	 shows	 mean	 percentage	 inhibition	 (%	
Inhibition)	 from	 duplicate	 experiments	 with	 error	 bars	 showing	 standard	
deviation.	Positive	control	is	shown	as	no	antibody	control.	Negative	control	uses	
α-PfRh4	 antibody.	 (H)	 Non-linear	 regression	 curve	 fit	 of	 α-Fy6	 2c3,	 α-FyB,	 α-











































































































































































































































































































4.1 Divergence of DBP in P. vivax and other related species  
To	 examine	 genetic	 diversity	 of	 PvDBP	 and	 homologues,	 a	 phylogenetic	
tree	 was	 constructed.	 43	 protein	 sequences	 gathered	 from	 various	 Plasmodium	
spp	(P.	adleri,	P.	berghei,	P.	cynomolgi,	P.	falciparum,	P.	inui,	P.	knowlesi,	P.	ovale,	P.	
reichenowi,	 P.	 vivax,	 P.	 P.	 vivax-like,	 P.	 yoelli,	 and	 P.	 gonderi)	 using	 PlasmoDB	 or	
NCBI	 were	 subjected	 to	 neighbor	 joining	 method.	 The	 constructed	 maximum	
likelihood	phylogenetic	tree	showed	DBP	homologues	of	P.	cynomolgi	and	P.	vivax	









containing	 gene	 in	 homologues	 of	 PvDBP,	 PcyDBP,	 PkDBP,	 and	 various	
common	isolates	known	to	infect	human	or	non-human	primates.		
The	analysis	was	conducted	using	neighbor-joining	method	with	1000	boostraps	
in	MegAlign	 (DNAstar).	 Red	 boxed	 regions	 indicate	 genes	 belonging	 to	P.	 vivax,	
and	 blue	 boxed	 regions	 indicate	 genes	 to	 P.	 cynomolgi	Berok.	 Numbers	 shown	
along	 nodes	 indicate	 boostrap	 values.	 Plasmodium	 spp,	 strain,	 gene	 name,	 and	








4.2 DBP and DARC recombinant protein expression  
To	 examine	 role	 of	 PvDBP	 and	 homologues	 in	 conserved	 morphological	
trait	of	PvDBP	to	H.	sapiens	DARC	(HsDARC)	in	P.	vivax	and	related	simian	malaria,	
we	 first	 expressed	 region	 II	 domain	 in	 PvDBP,	homologues	 PcyDBP1,	 PcyDBP2,	
and	 PkDBPα	 parasitic	 ligands	 (PvDBP-RII,	 PcyDBP1-RII,	 PcyDBP2-RII,	 and	
PkDBPα-RII	 respectively)	 (Figure	 4.2A).	 For	 negative	 control,	 DBL-domain	 of	 P.	
falciparum	 EBA175	 (PfEBA175-RII)	 known	 to	 interact	 with	 Glycophorin	 A	 was	
expressed.	 In	 addition,	 ectodomain	 of	 one	 human	 and	 two	 macaque	 DARC	
recombinant	proteins	spanning	amino	acids	1	to	63	in	H.	sapiens	DARC	(HsDARC)	















Figure	 4.2	 Schematic	 diagram	 of	 ligand-receptor	 amino	 acid	 sequences	 in	
homologues	central	to	DBP-DARC	interaction.		
(A)	 Alignment	 of	 full	 length	 parasitic	 ligand	PvDBP	 and	 homologues.	Horizontal	
bars	 indicate	 length	 of	 protein	 sequence,	 black	 vertical	 bars	 indicate	 gaps	 in	
alignment.	 Region	 II	 domain	 was	 expressed	 as	 recombinant	 protein.	 Numbers	
beside	 gene	 or	 bars	 indicate	 amino	 acid	 residue	 length.	 (B)	 Alignment	 of	 full	
length	 host	 receptor	 HsDARC	 and	 MfDARC.	 Horizontal	 bars	 indicate	 length	 of	
protein	 sequence,	 black	 vertical	 bars	 indicate	 gaps	 in	 alignment.	 Recombinant	





4.3 DBP and DARC interaction 
To	 determine	 cross-species	 interaction	 of	 DBP	 homologues	 to	 HsDARC,	
MfDARC,	and	MfDARC(∆E23),	an	in	situ	protein	binding	assay	was	conducted	using	
recombinant	 proteins	 previously	 described.	 Aliquots	 were	 taken	 at	 Input,	
Unbound	and	Eluate,	and	recombinant	proteins	separated	via	reducing	SDS-PAGE.	
The	 input	 (I)	 lanes	 show	migration	 of	 all	 proteins	 which	 includes	 DBP	 and	 Fc-
conjugated	 DARC	 (50	 kDa).	 The	 unbound	 lanes	 (U)	 show	 ligand	 proteins	 not	
bound	to	Fc-conjugated	DARC	proteins,	and	eluate	lanes	(E)	show	bound	proteins.	
The	 binding	 interactions	 were	 tested	 in	 combinations	 between	 parasitic	 ligand	
and	host	receptor.		
	
PvDBP-RII	 (75	 kDa)	was	 observed	 to	 bind	HsDARC,	 and	 not	MfDARC	nor	
MfDARC(∆E23)	(Figure	4.4A).	P.	knowlesi	orthologue	PkDBPα-RII	(37	kDa)	bound	
all	 H.	 sapiens	 and	 M.	 fascicularis	 DARC	 (Figure	 4.4B).	 In	 P.	 cynomolgi	 DBPs,	
PcyDBP1-RII	 (73	kDa)	was	observed	 to	bind	H.	sapiens	 and	M.	fascicularis	DARC	
(Figure	4.4C),	whereas	paralogue	PcyDBP2-RII	(73	kDa)	did	not	bind	any	(Figure	
4.4D).	Interestingly,	MfDARC(∆E23)	showed	lesser	binding	with	PcyDBP1-RII	than	
MfDARC,	which	 suggests	Glutamic	 acid	 in	 Fy6	domain	 essential	 for	PcyDBP1-RII	
interaction.	 Negative	 control	 P.	 falciparum	 erythrocyte	 binding	 antigen	 175	








Figure	 4.3	 In	 situ	 protein	 binding	 assay	 of	 DBP	 to	 DARC	 recombinant	
proteins.	
Fractions	of	 input	 (I),	unbound	 (U),	 and	eluate	 (E)	were	 run	on	a	 reducing	SDS-




PkDBPα-RII	 to	 DARC	 (C)	 Binding	 of	 PcyDBP1-RII	 to	 DARC	 (D)	 Binding	 of	
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4.4 Divergence of RBP2b in P. vivax and other related species  
To	 examine	 relatedness	 of	 RBP	 homologues,	 a	 phylogenetic	 tree	 was	
constructed	using	57	RBP	sequences	(homologues	RBP1a,	RBP1b,	RBP2a,	RBP2b,	
RBP2c,	and	RBP3)	were	gathered	 from	various	Plasmodium	spp	(P.	cynomolgi,	P.	
vivax,	P.	 gonderi,	 P.	 inui,	 P.	 knowlesi,	 P.	malariae,	P.	 ovale,	and	P.	 vivax-like)	 from	












in	MegAlign	 (DNAstar).	 Red	 boxed	 regions	 indicate	 genes	 belonging	 to	P.	 vivax,	
and	 blue	 boxed	 regions	 indicate	 genes	 to	 P.	 cynomolgi	Berok.	 Numbers	 shown	
along	 nodes	 indicate	 boostrap	 values.	 Plasmodium	 spp,	 strain,	 gene	 name,	 and	










4.5 RBP2b and TfR1 recombinant proteins  




amino	acid	 residues	159	 to	1453	 (Figure	4.5A).	To	 explore	 essential	 amino	acid	




been	 shown	 to	 harbour	 reticulocyte	 binding	 properties	 [83,	 98],	 the	N-terminal	
domain	of	paralogs	PcyRBP1a	and	PcyRBP1b	were	also	expressed	for	amino	acid	
residues	160	to	1181,	and	137	to	1278	respectively	(Figure	4.5B	and	4.5C).	Then	
using	 SF21	 cell	 expression	 system,	 extracellular	 domain	of	 human	and	macaque	












P.	 vivax	 and	 P.	 cynomolgi	 Berok.	 Horizontal	 bars	 indicate	 length	 of	 protein	
sequence.	 Gaps	 in	 constructs	 indicate	 missing	 amino	 acid	 residues	 (black)	 in	
Clustal	W	alignment.	N-terminus	domain	was	expressed	as	recombinant	protein.	
Numbers	beside	gene	or	bars	indicate	start	and	end	amino	acid	residue	numbers.	
The	 N-	 and	 C-terminus	 regions	 were	 denoted	 by	 N	 and	 C	 respectively.	 Signal	
peptide	 is	 shown	 in	 blue	 (SP).	 (A)	 Full	 length	 PvRBP2b,	 PcyRBP2b,	 and	
recombinant	 proteins	 Pv2b161-1454	 and	 Pcy2b159-1453.	 Site-directed	 mutagenesis	
was	 performed	 on	 Pcy2b159-1453	 construct	 to	 generate	 Pcy2b(Arg590Ser)	 and	
Pcy2b(Ser604Tyr).	 Induced	mutation	back	to	Pv2b	amino	acid	residue	is	marked	
with	a	 red	asterisk	 (*).	Lastly,	 a	 shorter	 recombinant	Pcy2b167-469	was	generated	
for	protein	studies.	(B)	Full	length	PvRBP1a,	PcyRBP1a	and	recombinant	Pcy1a160-
1181	 (C)	 Full	 length	 PvRBP1b,	 PcyRBP1b,	 and	 recombinant	 Pcy1b137-1278	(D)	 Full	







4.6 PvRBP antibodies recognise PcyRBP recombinant proteins  
PcyRBP	 recombinant	 proteins	 were	 tested	 for	 cross-reactivity	 to	 PvRBP	
antibodies	by	coating	P.	vivax	and	P.	cynomolgi	recombinant	proteins	 in	enzyme-
linked	immunosorbent	assay	(ELISA)	plates	and	subjecting	proteins	to	PvRBP	and	
PcyRBP	 polyclonal	 (Figure	 4.6A	 –	 4.6J)	 and	 monoclonal	 (Figure	 4.6K	 –	 4.6S)	
antibodies.	In	this	assay,	P.	falciparum	reticulocyte	homolog	4	antibody	(α-PfRh4)	

















































































































































































































































































































































































































































































































Figure	4.6	ELISA	using	antibodies	 raised	 towards	P.	vivax	 and	P.	cynomolgi	
RBPs	to	analyse	binding	to	PcyRBP1a160-1181,	PcyRBP1b137-1278,	PcyRBP2b159-
1453,	Pcy2b(Arg590Ser),	and	Pcy2b(Ser604Tyr)	recombinant	proteins.		
ELISA	 using	 antibodies	 raised	 to	 various	 recombinant	P.	 vivax	 homologous	 RBP	























































































































































































































































































PvRBP1a160-1170	 (Pv1a),	 PcyRBP1a160-1181	 (Pcy1a),	 PvRBP1b140-1275	 (Pv1b),	
PcyRBP1b137-1278	 (Pcy1b),	 PvRBP2b161-1454	 (Pv2b),	 PcyRBP2b159-1453	 (Pcy2b),	
mutants	 Pcy2b(Arg590Ser),	 and	 Pcy2b(Ser604Tyr).	 Negative	 control	 acquired	
Bovine	 Serum	 Albumin	 (BSA).	 (A	 to	 F)	 Polyclonal	 PvRBP	 antibodies.	 (G	 to	 I)	
Polyclonal	PcyRBP	antibodies	(J)	Control	P.	falciparum	Rh428-766	(PfRh4)	antibody.	
(K	and	L)	Mouse	monoclonal	PvRBP1a	and	PvRBP1b	antibodies	respectively.	(M	
to	 P)	 Mouse	 monoclonal	 PvRBP2b	 antibodies.	 (Q	 to	 S)	 Human	 monoclonal	
PvRBP2b	 antibodies.	N=3	 ELISA	 tests.	 Absorbance	 readings	 of	 HRP-conjugated	








4.7 PcyRBP2b recombinant protein do not bind human reticulocytes   
The	 PvRBP	 family	 of	 proteins	 have	 been	 implicated	 in	 binding	 human	
reticulocytes	 for	 merozoite	 invasion	 [83].	 It	 has	 been	 previously	 shown	 that	 P.	
cynomolgi	 Berok	 erythrocytic	 merozoites	 prefer	 to	 invade	 CD71+	 human	 cord	
blood	 reticulocytes	 in	 in	 vitro	 invasion	 assays.	 To	 determine	 if	 preference	 for	
CD71,	 also	 TfR1,	 depended	 on	 interaction	with	 orthologue	PcyRBP2b,	 a	 binding	
assay	was	conducted	using	Pv2b161-1454	and	Pcy2b159-1453	recombinant	proteins	at	
10,	5,	and	2.5	μg,	and	detected	using	Alexa	647	bound	α-Pv2b	polyclonal	antibody	
with	 enriched	 reticulocytes.	 Human	 cord	 blood	 reticulocytes	 were	 positively	
stained	 with	 Thiazole	 Orange	 (TO),	 and	 co-stained	 with	 Alexa	 647	 secondary	
antibody	 (2ab)	 for	negative	 control.	 In	 the	negative	 control,	 a	positive	Alexa	647	
signal	detected	at	 the	 tail	of	 the	negative	population	was	probably	derived	 from	
non-specific	 binding	 of	 reticulocytes	 to	 α-Pv2b	 polyclonal	 antibody.	 The	 double	
positive	population	was	determined	using	2ab	and	TO	negative	control.	Our	data	








Figure	 4.7	 Binding	 of	 PvRBP2b	 and	 PcyRBP2b	 recombinant	 proteins	 to	
reticulocytes.	
(A)	Dot	plots	show	reticulocyte	population	stained	with	Thiazole	orange	(TO)	on	
x-axis	 binding	 to	 10	 μg,	 5	 μg,	 and	 2.5	 μg	 of	 PvRBP2b161-1454	 (first	 row)	 and	
PcyRBP2b159-1453	 (second	 row)	 detected	 with	 α-PvRBP2b	 polyclonal	 antibody	


































4.8 PcyRBP2b recombinant protein does not form a complex with 
HsTfR1/Tf 
To	 investigate	 if	 P.	 cynomolgi	 Berok	 K2	 preference	 for	 CD71+	 human	
reticulocytes	 is	 facilitated	 by	 interaction	 between	 transferrin	 receptor	 (CD71+)	
and	PcyRBP2b	[88],	an	immunoprecipitation	assay	was	conducted.	This	assay	uses	
human	monoclonal	 antibodies	 (huMabs)	 bound	 to	 protein	 G	 beads	 to	 bind	 and	
elute	 either	Pv2b161-1454	or	Pcy2b159-1453.	 Aliquots	were	 taken	 at	 Input,	 Unbound	
and	Eluate,	and	recombinant	proteins	separated	via	reducing	SDS-PAGE.	The	input	
(I)	lanes	show	migration	of	all	proteins	which	includes	RBP2b	(153	kDa),	HsTfR1	
and	HsTf	 (70	 to	 75	 kDa),	 huMab	heavy	 chain	 (huMab	Hc)	 (60	 kDa),	 and	huMab	
light	chain	(huMab	Lc)	(25	kDa).	The	unbound	lanes	(U)	show	ligand	proteins	not	
bound	 to	 huMab,	 and	 eluate	 lanes	 (E)	 show	 bound	 proteins.	 The	 huMabs	 co-









Figure	 4.8	 Co-immunoprecipitation	 of	 Pv2b161-1454	 and	 Pcy2b159-1453	
recombinant	 proteins	 to	 HsTfR1/Tf	 using	 PvRBP2b	 human	 monoclonal	
antibody.		





(Right	 gel)	 P.	 cynomolgi	 RBP2b159-1453	 (PcyRBP2b159-1453,	 Pcy2b)	 recombinant	







4.9 Cross species interaction of RBP2b with M. fascicularis TfR1/Tf 
The	 lack	 of	 binding	 between	 PcyRBP2b	 and	 HsTfR1/Tf	 recombinant	
proteins	 may	 be	 that	 PcyRBP2b	 has	 evolved	 to	 only	 interact	 with	 TfR1/Tf	
cynomolgi’s	 in	 natural	 host	 species,	 M.	 fascicularis	 (MfTfR1/Tf).	 To	 test	 this	
hypothesis,	 a	 co-immunoprecipitation	 assay	 was	 conducted	 using	 recombinant	
MfTfR1/Tf	 proteins.	 The	 input	 (I)	 lanes	 show	 migration	 of	 all	 proteins	 which	
includes	 RBP2b	 (153	 kDa),	 TfR1	 and	 Tf	 (70	 to	 75	 kDa),	 huMab	 heavy	 chain	
(huMab	Hc)	(60	kDa),	and	huMab	light	chain	(huMab	Lc)	(25	kDa).	The	unbound	












Figure	 4.9	 Co-immunoprecipitation	 of	 Pv2b161-1454	 and	 Pcy2b159-1453	
recombinant	 proteins	 to	HsTfR1/Tf	 and	MfTfR1/Tf	 using	PvRBP2b	 human	
monoclonal	antibody.		
Co-immunoprecipitates	 of	 Input	 (I),	 Unbound	 (U),	 and	 Eluate	 (E)	 using	 human	
monoclonal	antibody	(huMab)	were	run	on	a	reducing	SDS-PAGE	gel	and	stained	
with	 Coomassie	 Blue.	 Presence	 of	 protein	 bands	 were	 indicated	 as	 (+),	 and	
absence	 as	 (-).	 Cross	 species	 interaction	 tests	 P.	 vivax	 RBP2b161-1454	 (Pv2b),	 P.	
cynomolgi	 RBP2b159-1453	 (Pcy2b)	 to	 H.	 sapiens	 TfR1/Tf	 (HsTfR1/Tf)	 and	 M.	







4.10 Cross species interaction of PcyRBP2b mutant proteins and 
TfR1/Tf 
The	 lack	 of	 binding	 between	 orthologue	 PcyRBP2b	 recombinant	 protein	
and	 TfR1/Tf,	 suggested	 that	 amino	 acid	 differences	 from	 PvRBP2b	 may	 affect	
certain	 critical	 interaction	 residues	 required	 for	 binding	 to	TfR1/Tf,	 such	 as	 the	
salt	bridge,	hydrophobic	pockets,	 and	 three	 tyrosine	motifs	 [88].	Here,	we	 listed	
several	amino	acid	 residues	of	RBP2b	 in	P.	vivax	strains	 (Salvador	 I	 and	PvP01),	
and	 P.	 cynomolgi	 strains	 (Bastianellii,	 Cambodian,	 and	 K4-A7)	 and	 compared	




residues	 facing	TfR1/Tf	 in	Pcy2b,	 a	protein	model	was	 threaded	 in	 Swiss-Model	
using	PvRBP2b	template	(PDB	ID:	5W53),	and	aligned	to	5W53	using	Coot.	Pcy2b	




(hydrogen	 bond),	 Asn531Asp	 (salt	 bridge),	 Arg590Ser	 (hydrogen	 bond),	 and	
Ser604Tyr	 (hydrophobic).	 We	 conducted	 site-directed	 mutagenesis	 (SDM)	 on	
Pcy2b	 plasmid	 and	 successfully	 attained	 Pcy2b(Arg590Ser)	 responsible	 for	
hydrogen	bond	 in	Pv2b,	and	Pcy2b(Ser604Tyr)	 part	 of	 a	 three	 tyrosine	motif	 in	
Pv2b,	 to	 examine	 if	 amino	 acid	 residues	 swapped	 to	 PvRBP2b	 could	 aid	 with	
complex	formation	to	TfR1/Tf.	
	
A	 co-immunoprecipitation	 assay	 was	 conducted	 to	 evaluate	 complex	
















Pcy2b(Arg590Ser)	 and	 Pcy2b(Ser604Tyr)	 recombinant	 proteins	 to	
HsTfR1/Tf	 (Hs)	 and	 MfTfR1/Tf	 (Mf)	 using	 PvRBP2b	 human	 monoclonal	
antibody.		
(A)	Comparison	of	RBP2b	amino	acid	residues	(AA	residue)	in	P.	vivax	Salvador-1	
(PvSal-1)	 and	 PvP01),	 P.	 cynomolgi	 Cambodian	 (PcyC),	 P.	 cynomolgi	Bastianellii	
A
Species / AA residue 297 304 359 428 527 530 531 538 541 542 556 563 586 590 600 603 604
PvSal-1 K R R N N E D Y S Y E K S S K D Y
PvP01 K R R N N E D Y S Y E K S S K D Y
PcyC K R R N D N N Y S Y E K S R K D S
PcyB K R R N D N N Y S Y E K S R K D S
K4-A7 K R T N D N N Y S Y E I S R K D S




(PcyB),	 K4-A7	 and	PcyRBP2b159-1453	(rPcy2b).	 Colour	 of	 text	 indicate	 amino	 acid	
when	 swapped	 to	 Alanine	 with	 either	 no	 defect	 (green),	 moderate	 (orange)	 or	
complete	 defect	 (red)	 in	 PvRBP2b	 mutational	 analysis	 respectively	 [88].	




SDS-PAGE	 gel	 and	 stained	with	 Coomassie	Blue.	 Positive	 bands	 are	 indicated	 as	
(+),	and	missing	bands	as	(-).	Pcy2b(Arg590Ser)	and	Pcy2b(Ser604Tyr)	were	co-
immunoprecipitated	 with	 either	 H.	 sapiens	 TfR1/Tf	 (Hs)	 and	 M.	 fascicularis	








4.11 Paralogous RBP proteins and TfR1/Tf 
Due	to	the	lack	of	binding	between	PcyRBP2b	and	its	mutant	proteins	with	
TfR1/Tf	 of	 human	 and	 macaque	 species,	 we	 examined	 if	 P.	 cynomolgi	 Berok	
preference	 for	 human	 reticulocytes	 via	 transferrin	 receptor	 could	 have	 been	
carried	 over	 to	 duplicated	 homologues	 P.	 cynomolgi	RBP1a	 (PcyRBP1a)	 and	 P.	
cynomolgi	 RBP1b	 (PcyRBP1b)	 proteins.	 The	 co-immunoprecipitation	 assay	 was	
conducted	with	mouse	monoclonal	antibodies	4E3	which	recognises	PvRBP1a160-
1170	(Pv1a160-1170)	and	PcyRBP1a160-1181	(Pcy1a160-1181),	and	 4G4	which	 recognises	




not	 bound	 to	 mMab,	 and	 eluate	 lanes	 (E)	 show	 bound	 proteins.	 While	 the	












Figure	 4.11	 Co-immunoprecipitation	 of	 PvRBP1a,	PvRBP1b,	PcyRBP1a,	and	
PcyRBP1b	to	 recombinant	 proteins	HsTfR1/Tf	 and	MfTfR1/Tf	 using	mouse	
monoclonal	antibodies.		
Co-immunoprecipitates	 (Co-IP)	 of	 Input	 (I),	 Unbound	 (U),	 and	 Eluate	 (E)	 using	
mouse	monoclonal	antibodies	(mMab)	were	run	on	a	reducing	SDS-PAGE	gel	and	
stained	 with	 Coomassie	 Blue.	 Positive	 bands	 are	 indicated	 as	 (+),	 and	 missing	
bands	as	(-).	(A)	Co-IP	of	PvRBP1a160-1170	(Pv1a160-1170,	Pv1a)	and	PcyRBP1a160-1181	
(Pcy1a160-1181,	Pcy1a)	 to	H.	sapiens	TfR1/Tf	 (Hs)	 and	M.	 fascicularis	TfR1/Tf	 (Mf)	
recombinant	proteins	using	mMab	4E3.	(B)	Co-IP	of	PvRBP1b140-1275	(Pv1b140-1275,	









4.12 PcyRBP2b protein binds MfDARC  
While	 no	 binding	was	 detected	 between	PcyRBP2b	 to	 TfR1/Tf	 of	 human	
and	macaque	species,	we	hypothesized	that	subfunctionalization	to	occur	 from	a	




To	 determine	 interaction	 of	 RBP2b	 with	 human	 and	 macaque	 Duffy	
receptor,	 we	 performed	 an	 in-situ	 protein	 binding	 assay	 using	 recombinant	
HsDARC,	MfDARC,	 and	MfDARC(∆E23)	 conjugated	 to	 Fc	 protein,	 and	 examined	
complex	 formation	to	PvRBP2b161-1454	and	PcyRBP2b159-1453	recombinant	proteins	






This	 preliminary	 data	 show	 PvRBP2b161-1454	 (Pv2b)	 to	 not	 bind	 HsDARC,	
MfDARC	 and	MfDARC(∆E23))	 (Figure	 4.12A).	 Instead,	 a	 weak	 PcyRBP2b159-1453	
(Pcy2b)	protein	band	was	observed	in	 in-situ	binding	with	MfDARC	and	HsDARC,	
but	 not	MfDARC(∆E23)	 (Figure	 4.12B).	The	 preliminary	 data	 suggests	 that	 the	














Figure	 4.12	 In	 situ	 protein	 binding	 assay	 of	 Fc-conjugated	 human	 and	
macaque	 DARC	 recombinant	 proteins	 to	 PvRBP2b	 and	 PcyRBP2b	
recombinant	proteins.	











4.13 RBP expression in P. cynomolgi Berok K4-A7  





as	 negative	 control.	 The	 nucleus	 of	 each	 merozoite	 was	 labelled	 with	 4′,6-
diamidino-2-phenylindole	 (DAPI),	 and	 images	 were	 shown	 as	 single	 captions,	
fluorescently	merged	(FL	merge),	and	with	brightfield	(merge).	
	 	













Figure	 4.13	 Immunofluorescence	 labelling	 of	 PcyRBP1a,	 PcyRBP1b,	 and	
PcyRBP2b	proteins	in	K4-A7	schizonts	
K4-A7	culture	was	matured	to	late-stage	parasites,	and	schizonts	concentrated	via	
MACS	 LD	 column.	 Parasitized	 erythrocytes	 were	 permeabilized	 and	 fixed	 with	
acetone,	 immunolabeled	 α-Pcy1a	 (A),	 α-Pcy1b	 (B),	 and	 α-Pcy2b	 (C)	 rabbit	




antibody	 (red).	 Merozoite	 nuclei	 visualization	 was	 stained	 using	 DAPI	 (blue).	














5.1 SMIM1 genotype  
The	recent	identification	of	Small	Integral	Membrane	Protein	1	(SMIM1),	an	
erythroleukemia	 gene,	 underlying	 the	 regulation	 of	 Vel	 blood	 group	 system	 has	
uncovered	 unique	 single	 nucleotide	 polymorphisms	 (SNPs)	 signatures	 globally.	
However,	 the	 function	 of	 erythroid	 Vel	 transmembrane	 protein	 has	 yet	 to	 be	
uncovered,	 and	 it	 is	 possible	 that	 pathogens	 use	 Vel	 as	 an	 invasion	 receptor,	
similar	to	how	P.	vivax	exploits	the	Duffy	blood	group	system.		
	
SMIM1	 sequencing	 showed	 Vel-negative	 individuals	 to	 encode	 a	
homozygous	 17-bp	 deletion	 in	 exon	 3,	 whereas	 Vel-positive	 controls	 had	 a	
consensus	 sequence.	 Besides	 the	 homozygosity	 deletion,	 two	 SNPs	 in	 intron	 2	
were	identified	to	abrogate	Vel	expression	in	Swedish	population	[99-101].	Within	
intron	2,	the	A/G	allele	of	rs1175550	was	found	associated	to	transcription	factor	
TAL1	 binding,	 with	 the	 A	 allele	 correlating	 positively	 with	 reduced	 protein	
expression	 and	 lower	 hemoglobin	 concentrations	 relative	 to	 G	 allele.	 Linked	 to	
this	 genotype	 is	 rs143702418C/CGCA	 genotypes	 where	 a	 C	 to	 CGCA	 insertion	
















(A)	 DNA	 sequencing	 chromatogram	 showing	 SMIM1	 genotypes	 in	 cord	 blood	










5.2 Rhesus factor in M. fascicularis  
The	R-C-E-F	system	in	MNS	blood	group	were	undetected	on	erythrocytes	
of	old	world	primates	[102].	To	confirm	this	genotyping,	RhD	and	RhCE	genes	are	
subjected	 to	 amplication	 using	M.	 fascicularis	and	H.	 sapiens	DNA	with	 primers.	









sapiens	RBC	 only	 (positive	 signal).	 Negative	 control	was	 shown	 using	 unstained	
1:1	mixture	of	macaque	:	human	RBC	(Unstain).	α-CD240DCE	showed	human	RBC	
population	 at	 46%	 in	1:1	mixture	 of	macaque	 :	 human	RBCs	 (Figure	5.2B).	 	We	
then	 combined	 α-CD240DCE	 with	 Hoechst	 34580	 (H34580)	 dye	 and	 examined	






















Figure	 5.2	 Rhesus	 factor	 to	 identify	 human	 RBCs	 in	 a	 mixed	 Human	 and	
Macaque	erythrocyte	culture.	





and	 unstain	 Hs	 +	Mf	RBC.	 APC-A	 subset	 show	 percentage	 of	 positively	 stained	





FM254	 FM255	 FM278 FM284 FM1303 Human
Gene Primers (Lanes	1,	7) (Lanes	2,	8) (Lanes	3,	9) (Lanes	4,	10) (Lanes	5,	11) (Lanes	6,	12)
RHD	exon	10 EX10F	and	RHD3'-UTR ✕ ✕ ✕ ✕ ✕ ✓




















Merozoites	 contain	 an	 apical	 prominence	where	 secretory	 organelles	 are	
localized	 for	 host	 cell	 entry.	 This	 includes	 the	 rhoptry,	 dense	 granules,	 and	
micronemes.	 Using	 TEM,	 we	 show	 ultrafine	 structures	 of	 P.	 cynomolgi	 Berok	
extracellular	merozoites	gaining	entry	to	M.	fascicularis	erythrocytes.	To	examine	
merozoite	 attachment,	 Cytochalasin	 D	 was	 applied	 to	 merozoites	 to	 block	




The	 images	 were	 arranged	 to	 show	 process	 of	 merozoite	 invasion	 -	
reorientation,	membrane	deformation,	and	entry.	Merozoites	randomly	encounter	
red	blood	cells	and	upon	recognition	undergo	reorientation	to	align	its	apical	(A)	
end	 to	 the	 host	 cell	 surface	 membrane	 (Figure	 6.3A).	 During	 reorientation,	 the	
merozoite	was	 observed	 to	 attach	 and	 glide	 along	 the	RBC	 surface	 (Figure	 6.3B	
and	6.3C).	When	the	apical	end	is	aligned,	a	tight	junction	is	formed,	and	invasive	
organelles	 such	 as	 micronemes,	 rhoptries	 and	 dense	 granules	 secrete	 binding	
proteins	to	bind	host	cell	surface	receptors	to	hijack	surface	receptors	to	undergo	




‘arm’	 located	 more	 than	 1	 μm	 away	 from	 its	 core	 body	 (Figure	 6.3E).	 The	






































gaining	 host	 cell	 entry	 into	M.	 fascicularis	erythrocytes.	Merozoite	 nucleus	were	
labelled	 (N).	 (A)	 Merozoite	 undergoing	 reorientation.	 The	 slight	 bump	 on	 the	





of	 merozoite	 attachment.	 (D)	 Tight	 junction	 formed	 with	 host	 cell	 and	
micronemes	 condensed	 into	 a	 pit	 against	 RBC	 surface.	 (E)	 Merozoite	 with	 an	
extended	 ‘arm’.	 The	 extended	 end	 contain	 electron	 dense	 particles	which	 could	
indicate	relocation	of	secretory	organelles.	Dense	granules	(DG)	contained	in	the	







6.2 P. cynomolgi Berok asexual merozoite development   
In	 erythrocytic	 development,	 in	 vitro	 P.	 cynomolgi	 Berok	 merozoites	
mature	 into	 trophozoites	 which	 undergo	 schizogony	 in	 a	 syncytial	 yet	
asynchronous	manner	within	48	h.	With	TEM,	we	observed	ultrafine	structures	of	
developing	 trophozoites	 and	 schizonts	 in	parasitized	M.	fascicularis	erythrocytes	
(Figure	 6.1A	 to	 6.1C),	 and	 observed	 structures	 not	 found	 in	 uninfected	
erythrocytes.	
	
In	 the	 erythrocyte,	 the	 parasite	 matures	 within	 the	 parasitophorous	
vacuolar	membrane	 (PVM)	and	digests	 cytoplasmic	hemoglobin.	The	by-product	
heme	 is	 toxic	 and	 the	 parasite	 converts	 it	 to	 inert	 hemozoin	 (Hz),	 which	 are	
observed	 as	 partially-stained	 crystalline	 shaped	 rods	 separately	 contained	 from	
merozoites	 in	 epoxy	 stained	 micrographs.	 During	 late	 stages	 of	 maturation,	
merozoite	 segmentation	 occurs	 concurrently	 with	 nuclear	 division	 in	 an	
asynchronous	 manner.	 A	 trophozoite	 developing	 into	 schizont	 stage	 would	
















Transmission	 electron	 micrographs	 of	 erythrocytic	 P.	 cynomolgi	 Berok	
trophozoites	 undergoing	 schizogony.	 (A)	 A	 cluster	 of	 budded	 merozoites.	
Merozoites	 individually	 contained	 nucleus	 (N),	 micronemes	 (Mn),	 and	 rhoptry	
(Rh).	By-product	Hemozoin	(Hz)	crystals	in	separate	compartment.	Maurer’s	cleft	
(MC)	 and	 caveola-vesicle	 complexes	 (CVC)	 located	 in	 parasitized	 erythrocyte	
cytoplasm.		(B)	Three	intracellular	merozoites	resides	to	the	left	and	a	trophozoite	
to	 the	 right	 of	 the	 red	 blood	 cell.	 Multiple	 CVC	 in	 erythrocyte	 cytoplasm	 (C)	 A	
trophozoite	resides	in	the	parasitophorous	vacuolar	membrane	(PVM)	undergoing	






6.3 Rosette formation  
The	 TEM	 micrographs	 also	 show	 another	 interesting	 host-parasite	
relationship	 involving	 localized	 red	 cell	 surface	 alterations	 resulting	 from	
exported	 parasitic	 proteins	 associated	 with	 severe	 disease	 pathology.	
Interestingly,	even	though	this	mechanism	is	conserved	in	all	Plasmodium	species,	
recent	 investigations	 show	 that	 rheology	 of	 parasitized	 erythrocytes	 differ	
amongst	 species.	 For	 P.	 falciparum,	 cytoadherence	 is	 regulated	 by	 erythrocyte	
membrane	 protein	 1	 (PfEMP1)	 and	 histidine-rich	 protein	 (HRP-1,	 KAHRP)	
forming	 PfEMP1-concentrated	 knobs	 to	 adhere	 circulating	 erythrocytes,	 often	
sequestered	 in	 cardiac	 venous	 endothelium	 and	 other	 organs	 [103].	 While	 the	
severe	 complications	 associated	 with	 P.	 falciparum	 rosettes	 are	 not	 a	 common	
phenomena	 seen	 in	P.	 vivax	 infections,	 there	 are	 increasing	 reports	 highlighting	
the	 capacity	 for	 severe	 vivax	malaria	 [104,	 105].	 Rosettes	 observed	 in	 ex	vivo	P.	
vivax	 and	 in	 vitro	 P.	 cynomolgi	 do	 not	 produce	 ‘knobby’	 characteristics	 like	 P.	
falciparum	[106].	Instead,	Schüffner	proposed	that	cytoplasm	is	pulled	apart	as	in	
threads	or	 ribbons	and	 spread	 throughout	 the	whole	 red	blood	corpuscle	 [107].	
Using	 TEM,	 we	 observed	 a	 portion	 of	 parasitized	 erythrocytes	 to	 mimic	 ‘hand-
holding’	 characteristics	where	protrusions	 of	 parasitized	RBC	 cytoplasm	 contact	
and	 fuse	 neighbouring	 uninfected	 RBC	 cytoplasm	 without	 plasma	 membrane	
(Figure	6.2A	to	6.2C).	When	tilt	series	 images	were	stacked	 into	a	 tomogram,	an	
open	 club-shaped	 pore	 situated	 on	 the	 PVM	 at	 the	 rosetting	 end	 of	 the	 iRBC,	
revealed	 two	 membrane-bound	 vesicles	 (V)	 adjacent	 to	 the	 pore	 in	 the	 iRBC	


















Transmission	 electron	 micrographs	 of	 erythrocytic	 P.	 cynomolgi	 Berok	
trophozoites	 making	 contact	 points	 with	 neighboring	 uninfected	 erythrocytes.	




dividing	 trophozoite	 with	 protruding	 erythrocyte	 membrane	 (Protrusion).	 The	
parasitophorous	 vacuolar	 membrane	 (PVM)	 contains	 the	 maturing	 trophozoite	
and	 hemozoin	 (Hz).	 Maurer’s	 cleft	 (MC)	 lie	 outside	 of	 PVM.	 (B)	 Parasitized	
erythrocyte	 with	 two	 protrusions	 extending	 and	 manipulating,	 ‘holding	 hands’	
with	 uninfected	 erythrocytes	 (C)	 Parasitized	 erythrocyte	 making	 contact	 with	





















Efforts	 to	 continuously	 culture	P.	 vivax	have	 not	 been	 successful,	despite	
heroic	 attempts	 to	 infect	 freshly	 hematopoietic	 or	 pluripotent	 stem	 cell	 derived	
CD71+	reticulocytes	[53].	Currently	most	of	our	fundamental	understanding	on	P.	
vivax	 biology	 has	 been	 derived	 from	 ex	 vivo	 studies	 [69]	 and	 a	 range	 of	
investigations	on	related	simian	malaria	species,	P.	knowlesi	[19]	and	P.	cynomolgi	
[63].	 In	 this	 study,	 a	 recently	 re-established	 P.	 cynomolgi	Berok	 erythrocytic	 in	
vitro	 culture	 [64,	 67]	 was	 optimized	 and	 its	 relatedness	 to	 the	 asexual	
development	of	P.	vivax	was	examined.	Specifically,	 this	study	utilized	a	range	of	
assays	 to	 investigate	 merozoite	 invasion	 into	 monkey	 RBCs	 and	 human	 CD71+	
reticulocytes,	 comparing	 inter-species	 ligand-receptor	 interactions	 and	mapping	
conserved	interactions.	
	
One	 of	 the	 key	 similarities	 between	P.	 cynomolgi	 and	 its	 sister	 species	P.	
vivax,	is	that	their	erythrocytic	merozoites	are	restricted	to	CD234+/CD71+	human	
cord	blood	reticulocytes	[65].	While	inherited	morphological	traits	are	indicators	
to	 ancestral	 characteristics,	 genetically	 homologous	 ligand-receptor	 interactions	
are	 interpreted	 to	perform	conserved	 functions	between	 closely	 related	 species.	
However,	 these	 parasites	 do	 have	 distinct	 natural	 hosts;	 P.	 vivax	 can	 naturally	
infect	 humans	 and	 apes	 [108],	 and	P.	 cynomolgi	 infect	 old	world	macaques	 and	
occasionally	 humans	 [94].	 Interestingly,	 essential	 binding	 proteins	 used	 for	
erythrocytic	merozoite	 invasion	such	as	Duffy	and	Reticulocyte	binding	proteins,	
do	 differ	 in	 copy	 numbers	 between	 P.	 cynomolgi	 and	 P.	 vivax	 [61].	Hence,	 the	
purpose	of	 this	study	 is	 to	explore	 inherited	morphological	 traits	 in	P.	cynomolgi	





7.2 Re-establish P. cynomolgi Berok erythrocytic continuous culture 
to further understand P. vivax invasion biology 
P.	cynomolgi	Berok	erythrocytic	in	vitro	culture	was	originally	isolated	and	
biologically	 filtered	 from	 a	 co-infected	 (P.	 fieldi	 and	 P.	 cynomolgi)	 pig-tailed	
macaque	 in	 the	 1960s,	 and	 later	 maintained	 by	 blood	 and/or	 sporozoite	
inoculation	 in	M.	mulatta	 and	 Aotus	monkeys	 [64,	 66].	 P.	 cynomolgi	Berok	 was	
later	revived	in	a	splenectomized	M.	fascicularis	(K1),	and	peripheral	parasites	for	
in	 vitro	 culture	 were	 established	 from	 a	 re-inoculated	 macaque	 (K2)	 [67].	 K4,	
derived	 from	 K2	 stabilite,	 showed	 robust	 routine	 culture	 for	more	 than	 a	 year.	
Likewise,	 K4-A7,	 derived	 from	 K4	 stabilite,	 was	 obtained	 via	 serial	 dilution	 to	
achieve	a	homogeneous	 clonal	 line	 capable	of	 sustainable	growth	 in	vitro,	which	
was	used	for	de	novo	sequencing.		
	






serum	 from	Australia,	 and	 developed	 a	 two-step	 screening	 procedure	 to	 negate	
donors	 with	 pre-existing	 Plasmodium	 spp.,	while	 selecting	 those	 which	 would	
support	P.	cynomolgi	Berok	growth	continuously.	Simultaneously,	a	proportion	of	
culture	was	subjected	to	schizont	enrichment	using	methods	based	on	established	
ex	 vivo	P.	 vivax	 invasion	 inhibition	 assays	 [69].	 Surprisingly,	 trypsin-Percoll	 and	
Percoll	 density	 centrifugation	methods	 applied	 to	 enrich	P.	vivax	schizonts	were	
unsuccessful	 in	P.	 cynomolgi	Berok	 (see	 Fig	 3.5).	 The	 negative	 impact	 of	 Percoll	




After	 the	 establishment	 of	 a	 tractable	 P.	 cynomolgi	 culture	 system	 at	









	Using	 the	 optimized	 P.	 cynomolgi	 Berok	 erythrocytic	 in	 vitro	 culture	
platform,	we	investigated	the	extent	to	which	the	erythrocyte	invasion	machinery	
of	 P.	 vivax	 is	 conserved	 in	 P.	 cynomolgi	 Berok	 by	 using	 comparative	 IIA	 (using	







7.3 Invasion inhibition and growth inhibition assays (IIA and GIA) 
Preliminary	 IIAs	 conducted	on	 the	Thai	Myanmar	border	with	 antibodies	
and	 peptides	 targeting	 PvRBP2b	 and	 SMIM1	 were	 unable	 to	 significantly	
determine	 if	 these	 antibodies	 and	 peptides	 were	 able	 to	 inhibit	 P.	 vivax	 or	 P.	
cynomolgi	Berok	merozoite	 invasion	 into	 human	 reticulocytes	 (see	 Fig	 3.9).	 The	
most	 important	 limitation	 facing	 this	 field	based	study	was	 the	 limited	access	 to	
sufficient	 biological	 replicates	 and	 the	 wide	 phenotypic	 variation	 in	 natural	
populations	 of	 P.	 vivax.	 Furthermore,	 the	 observed	 	 lack	 of	 significant	 invasion	
inhibition	 may	 have	 resulted	 from	 antibody	 non-specificity,	 and	 suboptimal	 P.	
vivax	merozoite	 invasion	 (compared	 to	P.	cynomolgi)	 due	 to	 naturally	 low	basal	
infection	 rates.	 In	 relation	 to	 this	 latter	 point,	 it	 should	 be	 noted	 that	 while	 P.	
cynomolgi	 infection	 rates	 into	 human	 reticulocytes	 were	 relatively	 consistent	
those	 of	P.	vivax	were	 understandably	 variable	 (see	 Fig	 3.8).	 Certainly,	 previous	
publication	showed	that	P.	vivax	invasion	rates	varied	from	0.1%	to	21.3%	[69].	As	
such,	 antibody	 specificity	 between	 species,	 and	 more	 biological	 resources	









viability	 stains.	 The	 impact	 of	 inhibition	 over	 two	 maturation	 cycles	 was	 an	
advantage	to	screen	and	identify	targets	of	protective	antibodies	against	P.	vivax.	
Interestingly,	 we	 observed	 α-2c6,	 an	 inhibitory	 PvDBP	 antibody,	 at	 a	 lower	
inhibitory	concentration	than	Duffy	antibody,	α-Fy6	2c3,	which	suggests	the	DBP-
DARC	binding	pocket	 in	 subdomain	3	of	DBP	 region	 II	 conserved	between	vivax	
and	cynomolgi	(see	Fig	3.10F).		
	




monkey	 RBCs.	 Even	 when	 examined	 at	 double	 the	 original	 concentration,	 α-
PvRBP1a	showed	contradictory	results	in	duplicated	tests.	In	this	specific	case,	an	
ongoing	 laboratory	 culture	 that	 provided	 the	 inoculum	 for	 the	 subsequent	
unsuccessful	 inhibition	 assay	 was	 ~six	 fold	 higher	 when	 compared	 to	 another	





to	 the	parasitaemias	of	 the	source/parental	 culture	as	 this	may	be	an	 important	
confounding	factor.	Despite	the	mixed	and	often	equivocal	results	seen	in	Fig	3.10	
we	 are	 confident	 these	 observations	 highlight	 the	 importance	 of	 GIA	 using	 P.	
cynomolgi	 in	 M.	 fascicularis	 erythrocytes	 to	 identify	 and	 streamline	 critical	
epitopes	 for	vivax	malaria	 vaccines	 [110].	 It	 is	 important	 to	note	 that	 this	 is	 the	








7.4 Duffy preference   
The	Duffy	Binding	Protein	 remains	 the	most	promising	vaccine	candidate	
against	 vivax	 malaria.	 While	 the	 majority	 of	 P.	 vivax	 infections	 are	 Duffy	




Fy	 is	 a	 type	 I	 transmembrane	 protein,	 and	 in	most	 cases	 essential	 for	P.	
vivax	 erythrocytic	 merozoite	 invasion	 [73].	 Although	 both	 P.	 vivax	 and	 P.	
cynomolgi	 Berok	 merozoites	 preferentially	 invade	 human	 cord	 blood	 CD71+	
reticulocytes,	Berok	showed	only	a	partial	 inhibition	when	incubated	with	α-Fy6	
2c3,	 and	 full	 inhibition	 with	 α-FyB.	 These	 results	 suggest	 that	 although	 Duffy	
preference	of		P.	cynomolgi	Berok	was	conserved	to	some	extent;	the	specific	DARC	
domains	used	by	its	merozoite	ligands	may	differ	to	that	of	P.	vivax.	Furthermore,	
we	 suspect	 that	P.	cynomolgi	may	have	a	 complex	 set	of	 redundant	pathways	 to	
effect	 the	duffy	dependant	 invasion	of	monkey	erythrocytes	not	observed	 in	 the	
human	invasion	assays.			
	
To	 help	 explain	 the	 discrepancy	 in	 conserved	 function	 between	 P.	
cynomolgi	 and	 P.	 vivax,	 in-situ	 protein	 binding	 assays	 were	 conducted	 using	
recombinant	proteins	to	parasitic	ligands	and	DARC	receptors.	Our	data	certainly	
supported	 P.	 cynomolgi’s	 use	 of	 the	 Fy6	 domain,	 however	 only	 to	 its	 natural	
macaque	 host	 -	 22SEDLW26.	 A	 reduction	 in	 PcyDBP1	 binding	 to	 M.	 fascicularis	
DARC	 encoding	 Fy6	 domain	 22S_DLW25,	 supports	 the	 observation	with	 Japanese	





the	generally	 conserved	Fy6	domain	 in	humans	 (both	 for	human	 infections	of	P.	
cynomolgi	 and	 P.	 vivax).	 This	 binding	 assay	 data	 points	 out	 differences	 in	










With	 regards	 to	 paralogue	 PcyDBP2,	 the	 interaction	 with	 DARC	 was	
dissimilar	 to	PcyDBP1	(no	binding	was	observed	 to	DARC	of	human	or	macaque	
species).	This	raises	a	lot	of	questions	to	the	function,	expression,	and	localisation	
of	 PcyDBP2,	 particularly	 during	 merozoite	 invasion.	 However,	 it	 may	 also	 be	
possible	 that	PcyDBP2	to	 function	 in	a	complex	with	other	binding	proteins,	 like	
that	of	P.	 falciparum	 protein	binding	 complex	 (consisting	of	 reticulocyte	binding	
homologue	 5	 (Rh5),	 Cysteine-rich	 protective	 antigen	 (CyRPA),	 and	 PfRh5-







7.5 Reticulocyte preference with RBP 1a, 1b and 2b  
Based	 on	 the	 solved	 ligand-receptor	 complex	 for	 erythrocytic	 P.	 vivax	
merozoites,	homologous	P.	cynomolgi	Berok	recombinant	proteins	were	generated	
to	explore	conserved	invasion	traits.	 In	this	study,	we	assumed	that	P.	cynomolgi	
Berok’s	PcyDBP1	and	PcyDBP2	had	 a	 similar	 preference	 to	DARC	as	 seen	 in	 the	
well	described	interaction	between		P.	vivax’s	PvDBP	and	DARC.	We	also	assumed	
that	 orthologous	 PcyRBPs	 play	 a	 similar	 role	 to	 PvRBPs	 in	 the	 preferential	
targeting/recognition	of	immature	reticulocytes.	Therefore,	our	study	focused	on	




Our	ELISA	data	 confirmed	α-PvRBP	pAbs	 recognized	 their	 respective	 and	
orthologous	 recombinant	 proteins,	 with	 Pcy2b	 showing	 no	 cross-reactivity	 to	
other	 PvRBP	 antibodies,	 but	 was	 instead	 recognized	 by	 PfRh4	 pAb	 (see	 Figure	
4.6A	 to	 J).	Although	 the	data	does	not	 suggest	 a	 shared	 function	between	PfRh4	
and	Pcy2b,	 there	 is	clearly	some	structural	homology	between	PfRh4	and	Pcy2b;	









human	 monoclonal	 antibodies	 (huMabs)	 which	 bound	 like	 8G7,	 mutant	
Pcy2b(Arg590Ser)	 showed	 stronger	 recognition	with	2***68	 (see	Figure	4.6Q	 to	
S).		
	
Unfortunately,	 no	 interactions	 were	 observed	 between	 TfR1/Tf	 of	
human/macaque	 species	 and	 reticulocyte	 binding	 recombinant	 proteins,	 which	





bind	membrane	 bound	 TfR1	 in	 RBC	 binding	 assay,	which	 suggests	P.	 cynomolgi	






Surprisingly,	 according	 to	 preliminary	 in-situ	protein	 binding	 data,	Pcy2b	
bound	 HsDARC,	 and	 MfDARC	 encoding	 22SEDLW26	 Fy6	 domain,	 but	 not	









7.6 Speculated role for CD71-clathrin pits in the merozoite invasion 
of erythrocytes 
Membrane	 deformation,	 a	 common	 characteristic	 exhibited	 by	
erythrocytes	 during	 the	 early	 phases	 of	 merozoite	 invasion,	 resulted	 from	 a	
combination	 of	 ligand-receptor	 interactions	 initiated	 by	 the	 merozoite.	 Early	
observations	of	this	process	using	TEMs	of	freshly	invaded	erythrocytes	show	the	
presence	 of	 several	 small	 vacuoles	 in	 the	 RBC	 cytoplasm	 near	 the	 merozoite	
attachment	site	[71].	Given	the	importance	of	the	CD71	receptor	to	invasion;	it	is	
plausible	 to	 suggest	 that	 these	 early	 ‘vacuoles’	 could	 possibly	 be	 clathrin	 pits	






Endocytic	 processes	 such	 as	 ferritin	 (iron)	 trafficking	 is	 most	 active	 in	
developing	 erythroblasts	 to	 synthesise	 hemoglobin	 [115].	 Iron	 trafficking	
essential	 for	 developing	 erythrocytes,	 is	 often	 regulated	 by	 interaction	 between	
TfR1	 and	 iron-loaded	 transferrin	 via	 clathrin-mediated	 endocytosis	 [116].	
However,	ferritin	uptake	does	not	trigger	the	plasma	membrane	to	extend	beyond	
it’s	 surface	and	 instead	 forms	small	 intracellular	pits	 for	endocytosis.	Hence,	my	
speculation	shares	with	the	proposed	receptor-mediated	endocytosis	and	extends	
towards	 macropinocytosis.	 In	 fact,	 many	 pathogens	 such	 as	 Legionella,	 Herpes	






that	 the	 number	 of	 vacuoles	 observed	 could	 be	 an	 indication	 to	 the	 number	 of	
membrane	veils	triggered	by	the	merozoite	(see	Figure	6.1F),	where	a	membrane	










7.7 Proposed rheopathology mechanism for P. vivax rosettes using P. 
cynomolgi Berok 
Most	 of	 our	 current	 understanding	 of	 malaria	 pathobiology	 and	 in	
particular	the	mechanisms	behind	the	cytoadherance	of	iRBCs	to	host	endothelia	
cells	and	uninfected	red	cells	(rosetting)	has	been	revealed	though	the	study	of	P.	
falciparum	 [55,	 118].	 In	P.	 falciparum,	cytoadherence	 to	 endothelial	 cells	 and/or	
uninfected	 erythrocytes	 is	 regulated	 by	 variant	 antigenic	 repeats	 (var)	 gene	
family,	 expressing	 PfEMP1	 concentrated	 on	 knob-like	 structures	 on	 late-stage	
iRBCs	[119,	120]	to	interact	with	endothelial	receptors	such	as	 	CD36	[121],	and	
Blood	 Group	 A	 trisaccharide	 [122,	 123].	 While	 the	 process	 by	 which	 PfiRBCs	
adhere	to	host	cells	is	well	documented,	such	interactions	are	poorly	understood	
in	 P.	 vivax.	 Our	 ability	 to	 culture	 and	 carefully	 examine	 the	 phenotype	 of	 P.	




and	 those	 of	 P.	 vivax	 (and	 P.	 cynomolgi)	 is	 the	 total	 absence	 of	 knobs	 on	 iRBC	
surface	in	these	latter	species.	In	the	knobless	vivax	like	iRBCs,	the	late-stages	are	
deformable	 and	 exhibit	 Schüffner’s	 dots	 associated	 with	 CVC	 regulated	 by	
Plasmodium	 helical	 interspersed	 sub-telomeric	 (PHIST)	 superfamily	 of	 proteins	
[107,	 124].	 Mechanical	manipulation	 of	 a	 two	 cell	 rosette,	 which	 consists	 of	 an	
infected	and	uninfected	cell,	requires	two	micropipette	aspirators	to	pull	the	cells	
apart.	In	the	initial	stages	of	separation,	the	videomicroscopy	reveal	a	visible	point	
of	 adherence	 which	 lengthens	 yet	 remains	 attached	 to	 the	 uninfected	 RBC	
membrane	 [106].	 Increasing	 the	 aspiration	 pressure	 to	 encourage	 the	 rosette	
separation,	 the	 point	 of	 adherence	 stretches	 into	 a	 thin	 membrane	 from	 the	
infected	 cell	 to	 the	 uninfected	 cell,	 while	 an	 indented	 crease	 was	 observed	 to	
surface	 under	 the	 uninfected	 erythrocyte	 plasma	 membrane.	 As	 the	 rosette	
continues	 to	 be	 pulled	 apart,	 the	 crease	 decreases	 in	 length,	 indicating	 that	 the	
point	of	adherence	could	be	extended	into	the	uninfected	erythrocyte	and	gently	






While	 we	 were	 attempting	 to	 localise	 PcyRBP2b	 in	 P.	 cynomolgi	 Berok	
using	 immuno-electron	 microscopy;	 we	 co-incidently	 observed	 cytoadherence	
structures	 associated	 with	 the	 adherence	 of	 uninfected	 RBCs	 with	 iRBCs	
containing	trophozoites	and	schizonts.	In	addition	to	the	clear	presence	of	CVC	in	
P.	cynomolgi	iRBCs,	we	also	noticed	that	the	surface	membrane	by	which	the	iRBCs	
are	 rosetting	 to	 the	 bound	 uninfected	 RBCs	 are	 shaped	 into	 a	 mushroom-like	
protrusion	(destitute	of	RBC	plasma	membrane	at	the	point	of	attachment	ranging	
from	75	to	1054	nm)	(see	Figure	6.3B).	The	rosetting	parasitized	erythrocyte	was	
observed	 with	 protruding	 cytoplasmic	 arms	 spiralling	 into	 the	 neighbouring	
erythrocytes’	 cytoplasm.	 Broader	 scale	 changes	 to	 the	 electron	 density	 of	 the	





rosette	 components.	 Importantly	 these	 rosettes	 associated	 protrusions	 (to	 the	
best	of	our	knowledge)	have	not	been	described	before	in	any	species	of	malaria	
parasite.	We	 are	 keen	 to	 further	 investigate	 the	 role	 of	 such	 protrusions	 in	 the	
formation	 of	 rosettes	 and	 whether	 such	 structures	 can	 be	 found	 in	 P.	 vivax	
rosettes.	 We	 are	 also	 interested	 to	 further	 study	 the	 specific	 role	 that	 these	
protrusions	 have	 on	 the	 stepwise	 process	 involved	 in	 the	 attachment	 of	 the	
uninfected	red	cell	to	the	iRBC.	Future	studies	involving	genetic	editing	of	putative	
rosetting	 ligands	 expressed	 on	 the	 surface	 of	 the	 iRBC	 (such	 as	 orthologous	 P.	
cynomolgi	vir	proteins)	are	now	possible	due	to	the	tractable	continuous	culture	of	







7.8 Conclusion and future directions 
In	 conclusion,	 P.	 vivax	 and	 P.	 cynomolgi	 Berok	 erythrocytic	 merozoites	
displayed	 conserved	 invasion	 preference	 for	 CD234+/CD71+	 cord	 blood	
reticulocytes.	In	addition	to	our	studies	on	host	cell	preference	we	also	dissected	a	





The	 Fy6	 preference	 in	 both	 P.	 vivax	and	 P.	 cynomolgi	Berok	 to	 their	 respective	
human	 and	 macaque	 host	 cells	 reflects	 conserved	 interactions	 between	
orthologous	 binding	 proteins	 and	 receptors	 (Figure	 7.1).	 Furthermore,	 we	
confirmed	that	there	was	no	significant	interaction	between	paralogue	PcyDBP2	to	
human	and	macaque	DARC.	The	lack	of	DARC	interaction	was	similarly	observed	










entry	 to	 host	 cells,	 parasites	 utilize	 merozoite	 ligands	 such	 as	 Duffy	 binding	
protein	 (DBP),	 Reticulocyte	 binding	 proteins	 (RBPs),	 and	 Merozoite	 surface	
proteins	 (MSPs)	 for	 interacting	 with	 H.	 sapiens	 reticulocyte	 receptors	 Duffy	
receptor	 (Fy),	 CD71,	 and	 possibly	 Band	 3	 /	 4.1R	 complex	 proteins	 respectively.	
This	study	examined	extent	of	conserved	interactions	to	their	functional	Duffy	and	
reticulocyte	 preferences.	 Solid	 lines	 connecting	 ligand	 to	 receptor	 illustrate	





is	 the	 possibility	 that	 PvDBP	 may	 have	 some	 role	 in	 the	 targeting	 of	 nascent	






a	 higher	 affinity	 for	 reticulocytes	 than	 RBPs	 (PvDBP-RII	 at	 Kd	 20	 to	 200nM	 as	
compared	to	PvRBPs	at	Kd	76	to	380nM)	[127].	These	finding	were	confirmed	in	a	
later	 study,	 clearly	 indicating	 a	 stronger	 reticulocyte	 binding	 associated	 with	
PvDBP-RII	than	PvRBP1a	[128].	In	a	recent	study	by	Han	et	al.,	(2016),	it	was	also	
noted	that	lower	concentration	of	PvDBP-RII	was	needed	to	saturate	reticulocyte	
binding	 as	 compared	 to	PvRBP1a-34	 and	PvRBP1b-32	 [98].	 In	 a	 separate	 study,	




the	 transferrin	 receptor	 (CD71).	 These	 preliminary	 data	 showing	 the	 binding	 of	
PvDBP	to	CD71	is	currently	being	repeated	by	one	of	our	collaborators.		
	
The	 subfunctionalization	 theory	 was	 similarly	 examined	 in	 orthologue	
PcyRBP2b.	 As	 no	 conserved	 interaction	 was	 observed	 between	 PcyRBP2b	 and	







other	 potential	 reticulocyte	 receptors	 to	 which	 P.	 vivax	erythrocytic	 merozoites	
will	 also	 utilize.	 To	 achieve	 this	 goal,	 the	 most	 common	 approach	 would	 be	 to	
evaluate	specific	binding	proteins	via	genetic	manipulation,	knocking	out	various	
target	 genes	 and	 assessing	 the	difference	 in	 subsequent	merozoite	 invasion	 and	
survival.	The	other	approach	is	to	generate	an	array	of	mutant	P.	cynomolgi	Berok	
parasites	 expressing	 P.	 vivax	 RBPs	 to	 evaluate	 binding	 with	 recombinant	
reticulocyte	proteins	to	which	these	ligands	could	bind	to.	In	this	way,	inhibitory	
monoclonal	 antibodies	 for	 vaccine	 development	 could	 also	 be	 investigated.	
Besides	 generating	mutant	 parasites,	 a	 high	 throughput	 screen	which	 evaluates	




such	 studies	 will	 not	 only	 provide	 a	 clear	 mechanistic	 explanation	 of	 P.	 vivax’s	
selection	 and	 invasion	 of	 reticulocytes,	 but	 also	 a	 pathway	 to	 discover	 key	
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